Anti-Ro	B-protein
(	I-protein
SSA	I-protein
)	I-protein
autoantibodies	I-protein
are	O
associated	O
with	O
T	B-DNA
cell	I-DNA
receptor	I-DNA
beta	I-DNA
genes	I-DNA
in	O
systemic	O
lupus	O
erythematosus	O
patients	O
.	O

Several	O
of	O
the	O
heterogeneous	O
clinical	O
manifestations	O
of	O
systemic	O
lupus	O
erythematosus	O
have	O
been	O
associated	O
with	O
specific	O
autoantibodies	B-protein
.	O

Associations	O
between	O
HLA	B-protein
class	I-protein
II	I-protein
antigens	I-protein
and	O
autoantibodies	B-protein
to	O
the	O
ribonucleoproteins	B-protein
Ro	B-protein
(	I-protein
SSA	I-protein
)	I-protein
and	O
La	B-protein
(	I-protein
SSB	I-protein
)	I-protein
have	O
been	O
reported	O
in	O
these	O
patients	O
.	O

Because	O
HLA	B-protein
class	I-protein
II	I-protein
molecules	I-protein
present	O
antigen	O
to	O
T	B-protein
cell	I-protein
receptors	I-protein
(	O
TCRs	B-protein
)	O
,	O
we	O
have	O
searched	O
for	O
a	O
TCR	B-DNA
gene	I-DNA
associated	O
with	O
the	O
production	O
of	O
anti-Ro	B-protein
(	I-protein
SSA	I-protein
)	I-protein
antibodies	I-protein
.	O

A	O
pair	O
of	O
restriction	B-DNA
fragment	I-DNA
length	I-DNA
polymorphisms	I-DNA
(	O
RFLPs	B-DNA
)	O
,	O
one	O
of	O
which	O
hybridizes	O
to	O
the	O
TCR	B-DNA
constant	I-DNA
region	I-DNA
C	I-DNA
beta	I-DNA
1	I-DNA
and	O
the	O
other	O
to	O
the	O
C	B-DNA
beta	I-DNA
2	I-DNA
gene	I-DNA
,	O
has	O
been	O
identified	O
,	O
suggesting	O
these	O
may	O
be	O
genotypic	O
markers	O
for	O
an	O
extended	O
region	O
of	O
the	O
TCR	B-DNA
beta	I-DNA
locus	I-DNA
.	O

This	O
RFLP	B-DNA
pair	I-DNA
occurs	O
in	O
76	O
%	O
of	O
patients	O
with	O
Ro	B-protein
(	I-protein
SSA	I-protein
)	I-protein
precipitins	O
,	O
84	O
%	O
of	O
anti-	O
Ro	B-protein
(	I-protein
SSA	I-protein
)	I-protein
-positive	O
patients	O
lacking	O
La	B-protein
(	I-protein
SSB	I-protein
)	I-protein
precipitins	B-protein
,	O
but	O
only	O
41	O
%	O
of	O
the	O
patients	O
lacking	O
both	O
precipitins	B-protein
(	O
P	O
=	O
0.0004	O
)	O
.	O

This	O
disproportionate	O
occurrence	O
in	O
a	O
subset	O
of	O
lupus	O
patients	O
indicates	O
that	O
these	O
RFLPs	B-DNA
are	O
not	O
disease	O
susceptibility	O
markers	O
,	O
but	O
rather	O
are	O
important	O
markers	O
for	O
TCR	B-DNA
genes	I-DNA
whose	O
products	O
are	O
involved	O
in	O
the	O
production	O
of	O
anti-Ro	B-protein
(	I-protein
SSA	I-protein
)	I-protein
antibodies	I-protein
.	O

The	O
majority	O
of	O
patients	O
who	O
have	O
these	O
RFLPs	B-DNA
and	O
HLA	B-protein
class	I-protein
II	I-protein
antigens	I-protein
previously	O
associated	O
with	O
the	O
anti-	O
Ro	B-protein
(	I-protein
SSA	I-protein
)	I-protein
response	O
make	O
this	O
antibody	O
,	O
suggesting	O
that	O
interactions	O
between	O
products	O
of	O
these	O
loci	B-DNA
occur	I-DNA
in	O
response	O
to	O
Ro	B-protein
(	I-protein
SSA	I-protein
)	I-protein
.	O

Anti-Ro	NULL
(	NULL
SSA	NULL
)	NULL
Autoantibodies	NULL
Are	NULL
Associated	NULL
with	NULL
T	NULL
Cell	NULL
Receptor	NULL
B	NULL
Genes	NULL
in	NULL
Systemic	NULL
Lupus	NULL
Erythematosus	NULL
Patients	NULL
Mark	NULL
Barton	NULL
Frank	NULL
,	NULL
*	NULL
Robert	NULL
McArthur	NULL
,	NULL
**	NULL
``	NULL
John	NULL
B.	NULL
Harley	NULL
,	NULL
***	NULL
and	NULL
Atsushi	NULL
Fujisaku*	NULL
*Arthritis	NULL
and	NULL
Immunology	NULL
Program	NULL
,	NULL
Oklahoma	NULL
Medical	NULL
Research	NULL
Foundation	NULL
;	NULL
*Department	NULL
of	NULL
Medicine	NULL
,	NULL
University	NULL
of	NULL
Oklahoma	NULL
Health	NULL
Sciences	NULL
Center	NULL
;	NULL
and	NULL
Veterans	NULL
Administration	NULL
Hospital	NULL
,	NULL
Oklahoma	NULL
City	NULL
,	NULL
Oklahoma	NULL
73104	NULL
Abstract	NULL
Several	NULL
of	NULL
the	NULL
heterogeneous	NULL
clinical	NULL
manifestations	NULL
of	NULL
systemic	NULL
lupus	NULL
erythematosus	NULL
have	NULL
been	NULL
associated	NULL
with	NULL
specific	NULL
autoantibodies	NULL
.	NULL

Associations	NULL
between	NULL
HLA	NULL
class	NULL
II	NULL
antigens	NULL
and	NULL
autoantibodies	NULL
to	NULL
the	NULL
ribonucleoproteins	NULL
Ro	NULL
(	NULL
SSA	NULL
)	NULL
and	NULL
La	NULL
(	NULL
SSB	NULL
)	NULL
have	NULL
been	NULL
reported	NULL
in	NULL
these	NULL
patients	NULL
.	NULL

Because	NULL
HLA	NULL
class	NULL
II	NULL
molecules	NULL
present	NULL
antigen	NULL
to	NULL
T	NULL
cell	NULL
receptors	NULL
(	NULL
TCRs	NULL
)	NULL
,	NULL
we	NULL
have	NULL
searched	NULL
for	NULL
a	NULL
TCR	NULL
gene	NULL
associated	NULL
with	NULL
the	NULL
production	NULL
of	NULL
anti-Ro	NULL
(	NULL
SSA	NULL
)	NULL
antibodies	NULL
.	NULL

A	NULL
pair	NULL
of	NULL
restriction	NULL
fragment	NULL
length	NULL
polymorphisms	NULL
(	NULL
RFLPs	NULL
)	NULL
,	NULL
one	NULL
of	NULL
which	NULL
hybridizes	NULL
to	NULL
the	NULL
TCR	NULL
constant	NULL
region	NULL
C	NULL
#	NULL
1	NULL
and	NULL
the	NULL
other	NULL
to	NULL
the	NULL
C32	NULL
gene	NULL
,	NULL
has	NULL
been	NULL
identified	NULL
,	NULL
suggesting	NULL
these	NULL
may	NULL
be	NULL
genotypic	NULL
markers	NULL
for	NULL
an	NULL
extended	NULL
region	NULL
of	NULL
the	NULL
TCR	NULL
locus	NULL
.	NULL

This	NULL
RFLP	NULL
pair	NULL
occurs	NULL
in	NULL
76	NULL
%	NULL
of	NULL
patients	NULL
with	NULL
Ro	NULL
(	NULL
SSA	NULL
)	NULL
precipitins	NULL
,	NULL
84	NULL
%	NULL
of	NULL
anti-Ro	NULL
(	NULL
SSA	NULL
)	NULL
-positive	NULL
patients	NULL
lacking	NULL
La	NULL
(	NULL
SSB	NULL
)	NULL
precipitins	NULL
,	NULL
but	NULL
only	NULL
41	NULL
%	NULL
of	NULL
the	NULL
patients	NULL
lacking	NULL
both	NULL
precipitins	NULL
(	NULL
P	NULL
=	NULL
0.0004	NULL
)	NULL
.	NULL

This	NULL
disproportionate	NULL
occurrence	NULL
in	NULL
a	NULL
subset	NULL
of	NULL
lupus	NULL
patients	NULL
indicates	NULL
that	NULL
these	NULL
RFLPs	NULL
are	NULL
not	NULL
disease	NULL
susceptibility	NULL
markers	NULL
,	NULL
but	NULL
rather	NULL
are	NULL
important	NULL
markers	NULL
for	NULL
TCR	NULL
genes	NULL
whose	NULL
products	NULL
are	NULL
involved	NULL
in	NULL
the	NULL
production	NULL
of	NULL
anti-Ro	NULL
(	NULL
SSA	NULL
)	NULL
antibodies	NULL
.	NULL

The	NULL
majority	NULL
of	NULL
patients	NULL
who	NULL
have	NULL
these	NULL
RFLPs	NULL
and	NULL
HLA	NULL
class	NULL
II	NULL
antigens	NULL
previously	NULL
associated	NULL
with	NULL
the	NULL
anti-Ro	NULL
(	NULL
SSA	NULL
)	NULL
response	NULL
make	NULL
this	NULL
antibody	NULL
,	NULL
suggesting	NULL
that	NULL
interactions	NULL
between	NULL
products	NULL
of	NULL
these	NULL
loci	NULL
occur	NULL
in	NULL
response	NULL
to	NULL
Ro	NULL
(	NULL
SSA	NULL
)	NULL
.	NULL

(	NULL
J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

1990	NULL
.	NULL

85:33-39	NULL
.	NULL
)	NULL

autoantibody	NULL
«	NULL
restriction	NULL
fragment	NULL
length	NULL
polymorphism	NULL
+	NULL
Ro	NULL
(	NULL
SSA	NULL
)	NULL
-	NULL
systemic	NULL
lupus	NULL
erythematosus	NULL
«	NULL
T	NULL
cell	NULL
receptor	NULL
Introduction	NULL
Systemic	NULL
lupus	NULL
erythematosus	NULL
(	NULL
SLE	NULL
)	NULL
!	NULL

is	NULL
a	NULL
rheumatic	NULL
disease	NULL
of	NULL
unknown	NULL
etiology	NULL
and	NULL
complex	NULL
pathogenesis	NULL
.	NULL

Its	NULL
study	NULL
is	NULL
complicated	NULL
by	NULL
diverse	NULL
clinical	NULL
manifestations	NULL
and	NULL
heterogeneous	NULL
laboratory	NULL
findings	NULL
.	NULL

Abundant	NULL
evidence	NULL
has	NULL
shown	NULL
the	NULL
importance	NULL
of	NULL
genetic	NULL
contributions	NULL
to	NULL
the	NULL
development	NULL
of	NULL
lupus	NULL
.	NULL

A	NULL
several	NULL
hundredfold	NULL
increase	NULL
in	NULL
the	NULL
incidence	NULL
of	NULL
the	NULL
disease	NULL
in	NULL
relatives	NULL
of	NULL
patients	NULL
compared	NULL
with	NULL
the	NULL
general	NULL
pop	NULL
Address	NULL
correspondence	NULL
to	NULL
Dr.	NULL
Bart	NULL
Frank	NULL
,	NULL
Arthritis	NULL
and	NULL
Immunology	NULL
Program	NULL
,	NULL
Oklahoma	NULL
Medical	NULL
Research	NULL
Foundation	NULL
,	NULL
825	NULL
N.E	NULL
.	NULL

1	NULL
3th	NULL
St.	NULL
,	NULL
Oklahoma	NULL
City	NULL
,	NULL
OK	NULL
73104	NULL
.	NULL

Received	NULL
for	NULL
publication	NULL
13	NULL
June	NULL
1989	NULL
and	NULL
in	NULL
revised	NULL
form	NULL
7	NULL
September	NULL
1989	NULL
.	NULL

1	NULL
.	NULL

Abbreviations	NULL
used	NULL
in	NULL
this	NULL
paper	NULL
:	NULL
CB	NULL
,	NULL
constant	NULL
region	NULL
gene	NULL
of	NULL
a	NULL
TCR	NULL
$	NULL
locus	NULL
;	NULL
RFLP	NULL
,	NULL
restriction	NULL
fragment	NULL
length	NULL
polymorphism	NULL
;	NULL
SLE	NULL
,	NULL
systemic	NULL
lupus	NULL
erythematosus	NULL
;	NULL
TCR	NULL
,	NULL
T	NULL
cell	NULL
receptor	NULL
;	NULL
VS	NULL
,	NULL
variable	NULL
region	NULL
gene	NULL
of	NULL
the	NULL
TCR	NULL
$	NULL
locus	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

©	NULL
The	NULL
American	NULL
Society	NULL
for	NULL
Clinical	NULL
Investigation	NULL
,	NULL
Inc.	NULL
0021-9738/90/01/0033/07	NULL
$	NULL
2.00	NULL
Volume	NULL
85	NULL
,	NULL
January	NULL
1990	NULL
,	NULL
33-39	NULL
ulation	NULL
exists	NULL
(	NULL
1	NULL
,	NULL
2	NULL
)	NULL
,	NULL
and	NULL
a	NULL
high	NULL
concordance	NULL
in	NULL
monozygotic	NULL
vs.	NULL
dizygotic	NULL
twins	NULL
has	NULL
been	NULL
reported	NULL
(	NULL
3	NULL
,	NULL
4	NULL
)	NULL
.	NULL

Associations	NULL
between	NULL
the	NULL
HLA	NULL
class	NULL
II	NULL
antigens	NULL
HLA-DR2	NULL
,	NULL
-DR3	NULL
,	NULL
and	NULL
-DR7	NULL
with	NULL
the	NULL
disease	NULL
exist	NULL
(	NULL
5-8	NULL
)	NULL
.	NULL

Because	NULL
of	NULL
linkage	NULL
disequilibrium	NULL
between	NULL
these	NULL
loci	NULL
and	NULL
others	NULL
in	NULL
the	NULL
HLA	NULL
region	NULL
,	NULL
it	NULL
remains	NULL
to	NULL
be	NULL
determined	NULL
whether	NULL
these	NULL
or	NULL
alleles	NULL
at	NULL
other	NULL
linked	NULL
loci	NULL
are	NULL
most	NULL
closely	NULL
associated	NULL
with	NULL
disease	NULL
predisposition	NULL
(	NULL
8-13	NULL
)	NULL
.	NULL

Recent	NULL
work	NULL
indicates	NULL
that	NULL
not	NULL
only	NULL
the	NULL
disease	NULL
as	NULL
a	NULL
whole	NULL
,	NULL
but	NULL
also	NULL
the	NULL
presence	NULL
of	NULL
particular	NULL
lupus	NULL
autoantibodies	NULL
are	NULL
associated	NULL
with	NULL
histocompatibility	NULL
genes	NULL
(	NULL
14-18	NULL
)	NULL
.	NULL

Ro	NULL
(	NULL
SSA	NULL
)	NULL
is	NULL
a	NULL
ribonucleoprotein	NULL
particle	NULL
consisting	NULL
of	NULL
a	NULL
polypeptide	NULL
chain	NULL
of	NULL
~60	NULL
kD	NULL
associated	NULL
with	NULL
one	NULL
of	NULL
four	NULL
small	NULL
(	NULL
83-112	NULL
base	NULL
)	NULL
RNA	NULL
molecules	NULL
(	NULL
19-22	NULL
)	NULL
.	NULL

This	NULL
complex	NULL
,	NULL
whose	NULL
function	NULL
is	NULL
currently	NULL
unknown	NULL
,	NULL
is	NULL
present	NULL
in	NULL
all	NULL
mammalian	NULL
cells	NULL
that	NULL
have	NULL
been	NULL
studied	NULL
.	NULL

Anti-Ro	NULL
(	NULL
SSA	NULL
)	NULL
autoantibodies	NULL
are	NULL
typically	NULL
found	NULL
in	NULL
30-50	NULL
%	NULL
of	NULL
lupus	NULL
patients	NULL
and	NULL
in	NULL
up	NULL
to	NULL
96	NULL
%	NULL
of	NULL
patients	NULL
with	NULL
primary	NULL
Sjogren	NULL
's	NULL
syndrome	NULL
(	NULL
21	NULL
,	NULL
23	NULL
)	NULL
.	NULL

In	NULL
lupus	NULL
patients	NULL
these	NULL
antibodies	NULL
are	NULL
associated	NULL
with	NULL
lymphopenia	NULL
,	NULL
photosensitive	NULL
dermatitis	NULL
,	NULL
and	NULL
pulmonary	NULL
disease	NULL
(	NULL
15	NULL
,	NULL
17	NULL
,	NULL
24-27	NULL
)	NULL
.	NULL

Antibodies	NULL
against	NULL
Ro	NULL
(	NULL
SSA	NULL
)	NULL
are	NULL
enriched	NULL
in	NULL
acid	NULL
eluates	NULL
of	NULL
nephritic	NULL
kidneys	NULL
of	NULL
lupus	NULL
patients	NULL
when	NULL
compared	NULL
with	NULL
their	NULL
serum	NULL
antibody	NULL
levels	NULL
,	NULL
suggesting	NULL
their	NULL
role	NULL
in	NULL
lupus	NULL
nephritis	NULL
(	NULL
28	NULL
)	NULL
.	NULL

Exogenous	NULL
anti-Ro	NULL
(	NULL
SSA	NULL
)	NULL
antibodies	NULL
deposit	NULL
in	NULL
human	NULL
skin	NULL
grafts	NULL
on	NULL
severe	NULL
combined	NULL
immune	NULL
deficiency	NULL
mice	NULL
in	NULL
patterns	NULL
similar	NULL
to	NULL
those	NULL
seen	NULL
in	NULL
skin	NULL
lesions	NULL
of	NULL
subacute	NULL
cutaneous	NULL
lupus	NULL
patients	NULL
(	NULL
29	NULL
)	NULL
.	NULL

The	NULL
close	NULL
association	NULL
of	NULL
maternal	NULL
anti-Ro	NULL
(	NULL
SSA	NULL
)	NULL
with	NULL
neonatal	NULL
dermatitis	NULL
and	NULL
complete	NULL
congenital	NULL
heart	NULL
block	NULL
further	NULL
suggests	NULL
a	NULL
pathogenic	NULL
role	NULL
for	NULL
these	NULL
antibodies	NULL
(	NULL
30-32	NULL
)	NULL
.	NULL

Patients	NULL
with	NULL
La	NULL
(	NULL
SSB	NULL
)	NULL
precipitins	NULL
constitute	NULL
a	NULL
subset	NULL
of	NULL
those	NULL
with	NULL
Ro	NULL
(	NULL
SSA	NULL
)	NULL
precipitins	NULL
.	NULL

This	NULL
patient	NULL
subset	NULL
differs	NULL
in	NULL
the	NULL
frequencies	NULL
of	NULL
the	NULL
HLA-DR2	NULL
and	NULL
-DR3	NULL
antigens	NULL
when	NULL
compared	NULL
with	NULL
those	NULL
having	NULL
only	NULL
anti-Ro	NULL
(	NULL
SSA	NULL
)	NULL
precipitins	NULL
(	NULL
11	NULL
,	NULL
15	NULL
)	NULL
.	NULL

In	NULL
lupus	NULL
patients	NULL
the	NULL
mutual	NULL
occurrence	NULL
of	NULL
both	NULL
antibodies	NULL
is	NULL
associated	NULL
with	NULL
a	NULL
low	NULL
frequency	NULL
of	NULL
renal	NULL
disease	NULL
when	NULL
compared	NULL
with	NULL
patients	NULL
with	NULL
only	NULL
anti-Ro	NULL
(	NULL
SSA	NULL
)	NULL
antibodies	NULL
(	NULL
17	NULL
,	NULL
24	NULL
)	NULL
,	NULL
and	NULL
a	NULL
high	NULL
prevalence	NULL
of	NULL
photosensitivity	NULL
,	NULL
discoid	NULL
rash	NULL
,	NULL
and	NULL
sicca	NULL
symptoms	NULL
(	NULL
23	NULL
,	NULL
24	NULL
,	NULL
33	NULL
,	NULL
34	NULL
)	NULL
.	NULL

In	NULL
the	NULL
absence	NULL
of	NULL
cytotoxic	NULL
chemotherapy	NULL
,	NULL
the	NULL
presence	NULL
of	NULL
both	NULL
of	NULL
these	NULL
antibodies	NULL
is	NULL
stable	NULL
irrespective	NULL
of	NULL
disease	NULL
activity	NULL
(	NULL
24	NULL
)	NULL
.	NULL

These	NULL
findings	NULL
suggest	NULL
that	NULL
genetic	NULL
and	NULL
clinical	NULL
differences	NULL
exist	NULL
between	NULL
the	NULL
anti-Ro	NULL
(	NULL
SSA	NULL
)	NULL
-positive	NULL
patients	NULL
with	NULL
and	NULL
without	NULL
the	NULL
anti-La	NULL
(	NULL
SSB	NULL
)	NULL
autoantibody	NULL
,	NULL
and	NULL
patients	NULL
lacking	NULL
the	NULL
anti-Ro	NULL
(	NULL
SSA	NULL
)	NULL
antibodies	NULL
.	NULL

Anti-Ro	NULL
(	NULL
SSA	NULL
)	NULL
autoantibodies	NULL
in	NULL
lupus	NULL
patients	NULL
have	NULL
been	NULL
associated	NULL
with	NULL
HLA	NULL
class	NULL
II	NULL
antigens	NULL
(	NULL
14-16	NULL
,	NULL
18	NULL
,	NULL
35	NULL
,	NULL
36	NULL
)	NULL
.	NULL

In	NULL
models	NULL
of	NULL
T	NULL
cell	NULL
activation	NULL
,	NULL
antigen	NULL
is	NULL
presented	NULL
by	NULL
MHC	NULL
proteins	NULL
to	NULL
the	NULL
T	NULL
cell	NULL
receptor	NULL
(	NULL
TCR	NULL
)	NULL
.	NULL

However	NULL
,	NULL
no	NULL
investigations	NULL
have	NULL
shown	NULL
differences	NULL
between	NULL
TCR	NULL
genes	NULL
of	NULL
lupus	NULL
patients	NULL
and	NULL
healthy	NULL
controls	NULL
(	NULL
37-39	NULL
)	NULL
.	NULL

These	NULL
studies	NULL
have	NULL
considered	NULL
lupus	NULL
as	NULL
a	NULL
single	NULL
disease	NULL
entity	NULL
without	NULL
consideration	NULL
of	NULL
the	NULL
heterogeneous	NULL
antibody	NULL
profiles	NULL
or	NULL
HLA	NULL
class	NULL
II	NULL
differences	NULL
of	NULL
these	NULL
patients	NULL
,	NULL
and	NULL
therefore	NULL
do	NULL
not	NULL
mean	NULL
that	NULL
important	NULL
rela-	NULL
T	NULL
Cell	NULL
Receptor	NULL
Genes	NULL
and	NULL
Anti-Ro	NULL
(	NULL
SSA	NULL
)	NULL
Antibodies	NULL
in	NULL
Systemic	NULL
Lupus	NULL
Erythematosus	NULL
_	NULL
33	NULL
tionships	NULL
with	NULL
TCRs	NULL
do	NULL
not	NULL
exist	NULL
.	NULL

In	NULL
this	NULL
study	NULL
we	NULL
have	NULL
investigated	NULL
the	NULL
role	NULL
of	NULL
TCRs	NULL
in	NULL
the	NULL
production	NULL
of	NULL
anti-Ro	NULL
(	NULL
SSA	NULL
)	NULL
antibodies	NULL
.	NULL

The	NULL
immunologically	NULL
defined	NULL
subgroup	NULL
of	NULL
patients	NULL
with	NULL
this	NULL
autoantibody	NULL
is	NULL
more	NULL
homogeneous	NULL
genetically	NULL
and	NULL
clinically	NULL
than	NULL
the	NULL
group	NULL
of	NULL
lupus	NULL
patients	NULL
as	NULL
a	NULL
whole	NULL
.	NULL

The	NULL
combination	NULL
of	NULL
a	NULL
new	NULL
restriction	NULL
fragment	NULL
length	NULL
polymorphism	NULL
(	NULL
RFLP	NULL
)	NULL
with	NULL
the	NULL
previously	NULL
described	NULL
Bgl	NULL
II	NULL
TCR	NULL
#	NULL
RFLP	NULL
permitted	NULL
us	NULL
to	NULL
identify	NULL
a	NULL
genotypic	NULL
marker	NULL
that	NULL
is	NULL
strongly	NULL
associated	NULL
with	NULL
anti-Ro	NULL
(	NULL
SSA	NULL
)	NULL
autoantibodies	NULL
.	NULL

Our	NULL
data	NULL
further	NULL
suggested	NULL
that	NULL
a	NULL
TCR	NULL
gene	NULL
product	NULL
may	NULL
interact	NULL
with	NULL
particular	NULL
HLA	NULL
class	NULL
II	NULL
antigens	NULL
in	NULL
the	NULL
development	NULL
or	NULL
perpetuation	NULL
of	NULL
this	NULL
autoimmune	NULL
response	NULL
.	NULL

This	NULL
is	NULL
the	NULL
first	NULL
example	NULL
of	NULL
an	NULL
association	NULL
between	NULL
a	NULL
TCR	NULL
gene	NULL
and	NULL
an	NULL
immune	NULL
response	NULL
to	NULL
a	NULL
known	NULL
autoantigen	NULL
in	NULL
humans	NULL
.	NULL

Methods	NULL
DNA	NULL
probes	NULL
.	NULL

Human	NULL
cDNA	NULL
(	NULL
40	NULL
)	NULL
subcloned	NULL
in	NULL
pBR322	NULL
was	NULL
graciously	NULL
provided	NULL
by	NULL
J.	NULL
D.	NULL
Capra	NULL
(	NULL
University	NULL
of	NULL
Texas	NULL
Southwestern	NULL
Medical	NULL
Center	NULL
,	NULL
Dallas	NULL
,	NULL
TX	NULL
)	NULL
.	NULL

The	NULL
770-bp	NULL
Pst	NULL
I	NULL
insert	NULL
was	NULL
electropho-retically	NULL
isolated	NULL
from	NULL
the	NULL
plasmid	NULL
DNA	NULL
and	NULL
digested	NULL
with	NULL
Bgl	NULL
II	NULL
.	NULL

A	NULL
~	NULL
400-bp	NULL
fragment	NULL
that	NULL
contained	NULL
the	NULL
first	NULL
,	NULL
second	NULL
,	NULL
and	NULL
a	NULL
few	NULL
nucleotides	NULL
of	NULL
the	NULL
third	NULL
exon	NULL
of	NULL
the	NULL
TCR	NULL
constant	NULL
region	NULL
(	NULL
CB	NULL
)	NULL
was	NULL
ligated	NULL
into	NULL
the	NULL
pUC19	NULL
vector	NULL
and	NULL
transformed	NULL
into	NULL
the	NULL
Escherichia	NULL
coli	NULL
strain	NULL
TBI	NULL
(	NULL
41	NULL
)	NULL
.	NULL

This	NULL
TCR	NULL
C	NULL
#	NULL
insert	NULL
was	NULL
isolated	NULL
using	NULL
a	NULL
preparative	NULL
5	NULL
%	NULL
N	NULL
,	NULL
N'-bis-acrylylcystamine	NULL
crosslinked	NULL
polyacrylamide	NULL
gel	NULL
(	NULL
Bio-Rad	NULL
Laboratories	NULL
,	NULL
Richmond	NULL
,	NULL
CA	NULL
)	NULL
and	NULL
DEAE-cellulose	NULL
ion-exchange	NULL
chro-matography	NULL
,	NULL
and	NULL
used	NULL
as	NULL
a	NULL
probe	NULL
in	NULL
this	NULL
study	NULL
.	NULL

Patients	NULL
and	NULL
DNA	NULL
protocols	NULL
.	NULL

A	NULL
minimum	NULL
of	NULL
30	NULL
ml	NULL
of	NULL
anticoagu-lated	NULL
peripheral	NULL
blood	NULL
was	NULL
collected	NULL
from	NULL
70	NULL
female	NULL
and	NULL
6	NULL
male	NULL
patients	NULL
diagnosed	NULL
with	NULL
SLE	NULL
(	NULL
42	NULL
)	NULL
.	NULL

The	NULL
average	NULL
patient	NULL
age	NULL
was	NULL
40.6	NULL
yr	NULL
,	NULL
with	NULL
a	NULL
range	NULL
of	NULL
22-80	NULL
yr.	NULL
46	NULL
patients	NULL
were	NULL
Caucasians	NULL
,	NULL
26	NULL
were	NULL
Black	NULL
,	NULL
3	NULL
were	NULL
American	NULL
Indians	NULL
,	NULL
and	NULL
1	NULL
was	NULL
Chinese	NULL
.	NULL

Peripheral	NULL
blood	NULL
samples	NULL
were	NULL
also	NULL
collected	NULL
from	NULL
25	NULL
healthy	NULL
individuals	NULL
.	NULL

No	NULL
one	NULL
in	NULL
the	NULL
latter	NULL
group	NULL
was	NULL
known	NULL
to	NULL
have	NULL
SLE	NULL
in	NULL
their	NULL
family	NULL
.	NULL

The	NULL
frequency	NULL
of	NULL
the	NULL
RFLPs	NULL
did	NULL
not	NULL
vary	NULL
with	NULL
the	NULL
age	NULL
or	NULL
sex	NULL
of	NULL
the	NULL
participants	NULL
.	NULL

The	NULL
frequency	NULL
of	NULL
one	NULL
RFLP	NULL
(	NULL
the	NULL
Bgl	NULL
II	NULL
9.8-kb	NULL
RFLP	NULL
)	NULL
was	NULL
slightly	NULL
increased	NULL
in	NULL
Blacks	NULL
when	NULL
compared	NULL
with	NULL
Caucasians	NULL
.	NULL

No	NULL
racial	NULL
differences	NULL
were	NULL
noted	NULL
in	NULL
the	NULL
frequency	NULL
of	NULL
the	NULL
Kpn	NULL
I	NULL
RFLPs	NULL
or	NULL
in	NULL
the	NULL
frequency	NULL
of	NULL
the	NULL
combined	NULL
Bgl	NULL
II	NULL
9.8-	NULL
and	NULL
Kpn	NULL
I	NULL
1.75-kb	NULL
RFLP	NULL
in	NULL
controls	NULL
or	NULL
in	NULL
patients	NULL
who	NULL
produced	NULL
the	NULL
anti-Ro	NULL
autoantibody	NULL
when	NULL
grouped	NULL
by	NULL
race	NULL
.	NULL

Because	NULL
of	NULL
these	NULL
preliminary	NULL
findings	NULL
and	NULL
the	NULL
small	NULL
number	NULL
of	NULL
individuals	NULL
present	NULL
in	NULL
racially	NULL
and	NULL
autoantibody-defined	NULL
groups	NULL
,	NULL
patients	NULL
were	NULL
pooled	NULL
irrespective	NULL
of	NULL
age	NULL
,	NULL
sex	NULL
,	NULL
or	NULL
race	NULL
in	NULL
this	NULL
study	NULL
.	NULL

Buffy	NULL
coat	NULL
leukocytes	NULL
were	NULL
lysed	NULL
with	NULL
1	NULL
%	NULL
Triton	NULL
X-100	NULL
(	NULL
Aldrich	NULL
Chemical	NULL
Co.	NULL
,	NULL
Milwaukee	NULL
,	NULL
WI	NULL
)	NULL
in	NULL
0.32	NULL
M	NULL
sucrose	NULL
,	NULL
10	NULL
mM	NULL
Tris-HCI	NULL
,	NULL
and	NULL
5	NULL
mM	NULL
MgCl	NULL
,	NULL
pH	NULL
7.5	NULL
.	NULL

The	NULL
centrifugal	NULL
pellet	NULL
was	NULL
resuspended	NULL
in	NULL
75	NULL
mM	NULL
NaCl	NULL
and	NULL
25	NULL
mM	NULL
EDTA	NULL
and	NULL
digested	NULL
with	NULL
200	NULL
ug/ml	NULL
proteinase	NULL
K	NULL
(	NULL
Bethesda	NULL
Research	NULL
Laboratories	NULL
,	NULL
Gaithersburg	NULL
,	NULL
MD	NULL
)	NULL
in	NULL
0.5	NULL
%	NULL
SDS	NULL
at	NULL
37°C	NULL
overnight	NULL
.	NULL

The	NULL
following	NULL
day	NULL
,	NULL
5	NULL
ug	NULL
RNAse	NULL
(	NULL
Sigma	NULL
Chemical	NULL
Co.	NULL
,	NULL
St.	NULL
Louis	NULL
,	NULL
MO	NULL
)	NULL
was	NULL
added	NULL
for	NULL
30	NULL
min	NULL
,	NULL
followed	NULL
by	NULL
four	NULL
phenol-CHCI	NULL
;	NULL
-isoamyl	NULL
alcohol	NULL
extractions	NULL
and	NULL
ethanol	NULL
precipitation	NULL
.	NULL

The	NULL
isolated	NULL
DNA	NULL
was	NULL
resuspended	NULL
in	NULL
1	NULL
ml	NULL
of	NULL
10	NULL
mM	NULL
Tris-HCl	NULL
and	NULL
1	NULL
mM	NULL
EDTA	NULL
.	NULL

10-ug	NULL
samples	NULL
of	NULL
DNA	NULL
were	NULL
digested	NULL
with	NULL
restriction	NULL
enzymes	NULL
in	NULL
buffer	NULL
provided	NULL
by	NULL
the	NULL
enzymes	NULL
'	NULL
suppliers	NULL
(	NULL
Promega	NULL
Biotech	NULL
[	NULL
Madi-son	NULL
,	NULL
WI	NULL
]	NULL
,	NULL
Boehringer	NULL
Mannheim	NULL
Biochemicals	NULL
[	NULL
Indianapolis	NULL
,	NULL
IN	NULL
]	NULL
,	NULL
and	NULL
Bethesda	NULL
Research	NULL
Laboratories	NULL
)	NULL
.	NULL

Samples	NULL
were	NULL
subjected	NULL
to	NULL
electro-phoresis	NULL
in	NULL
0.8	NULL
%	NULL
agarose	NULL
gels	NULL
in	NULL
TBE	NULL
buffer	NULL
(	NULL
0.1	NULL
M	NULL
Tris	NULL
,	NULL
0.1	NULL
M	NULL
boric	NULL
acid	NULL
,	NULL
and	NULL
2	NULL
mM	NULL
EDTA	NULL
at	NULL
pH	NULL
8.0	NULL
)	NULL
at	NULL
40	NULL
V	NULL
for	NULL
16-18	NULL
h.	NULL
DNA	NULL
was	NULL
transferred	NULL
to	NULL
nylon	NULL
membranes	NULL
(	NULL
Amersham	NULL
Corp.	NULL
[	NULL
Arlington	NULL
Heights	NULL
,	NULL
IL	NULL
]	NULL
or	NULL
Gelman	NULL
Sciences	NULL
,	NULL
Inc.	NULL
[	NULL
Ann	NULL
Arbor	NULL
,	NULL
MI	NULL
)	NULL
by	NULL
the	NULL
method	NULL
of	NULL
Southern	NULL
(	NULL
43	NULL
)	NULL
,	NULL
and	NULL
prehybridized	NULL
for	NULL
4	NULL
h	NULL
at	NULL
65°C	NULL
in	NULL
5	NULL
%	NULL
SSPE	NULL
(	NULL
0.75	NULL
M	NULL
NaCl	NULL
,	NULL
50	NULL
mM	NULL
NaH	NULL
;	NULL
PO	NULL
,	NULL
/H	NULL
;	NULL
0	NULL
,	NULL
5	NULL
mM	NULL
EDTA	NULL
,	NULL
pH	NULL
7.0	NULL
)	NULL
,	NULL
10	NULL
%	NULL
Den-hardt	NULL
's	NULL
solution	NULL
(	NULL
0.2	NULL
%	NULL
BSA	NULL
,	NULL
0.2	NULL
%	NULL
ficoll	NULL
,	NULL
0.2	NULL
%	NULL
polyvinylpyrrolidone	NULL
)	NULL
,	NULL
5	NULL
%	NULL
dextran	NULL
sulfate	NULL
,	NULL
0.1	NULL
%	NULL
SDS	NULL
,	NULL
50	NULL
mM	NULL
phosphate	NULL
buffer	NULL
,	NULL
and	NULL
50	NULL
ug/ml	NULL
34	NULL
-	NULL
M.	NULL
B.	NULL
Frank	NULL
,	NULL
R.	NULL
McArthur	NULL
,	NULL
J	NULL
.	NULL

B.	NULL
Harley	NULL
,	NULL
and	NULL
A.	NULL
Fujisaku	NULL
of	NULL
denatured	NULL
salmon	NULL
sperm	NULL
DNA	NULL
.	NULL

The	NULL
prehybridization	NULL
solution	NULL
was	NULL
replaced	NULL
with	NULL
fresh	NULL
solution	NULL
and	NULL
hybridization	NULL
was	NULL
performed	NULL
overnight	NULL
at	NULL
65°C	NULL
with	NULL
the	NULL
radiolabeled	NULL
TCR	NULL
CS	NULL
probe	NULL
(	NULL
44	NULL
,	NULL
45	NULL
)	NULL
.	NULL

Membranes	NULL
were	NULL
washed	NULL
at	NULL
high	NULL
stringency	NULL
with	NULL
0.2	NULL
%	NULL
SSPE	NULL
and	NULL
0.1	NULL
%	NULL
SDS	NULL
at	NULL
65°C	NULL
.	NULL

Sizes	NULL
of	NULL
RFLP	NULL
bands	NULL
were	NULL
estimated	NULL
by	NULL
autoradiography	NULL
(	NULL
X-Omat	NULL
AR	NULL
film	NULL
;	NULL
Eastman	NULL
Kodak	NULL
Co.	NULL
,	NULL
Rochester	NULL
,	NULL
NY	NULL
)	NULL
relative	NULL
to	NULL
the	NULL
migration	NULL
of	NULL
Hind	NULL
III-digested	NULL
lambda	NULL
bacteriophage	NULL
DNA	NULL
and	NULL
Hae	NULL
III-digested	NULL
phiX-174	NULL
DNA	NULL
(	NULL
Bethesda	NULL
Research	NULL
Laboratories	NULL
,	NULL
Gaithersburg	NULL
,	NULL
MD	NULL
)	NULL
.	NULL

Detection	NULL
of	NULL
patient	NULL
autoantibodies	NULL
.	NULL

Patient	NULL
sera	NULL
were	NULL
analyzed	NULL
for	NULL
the	NULL
presence	NULL
of	NULL
anti-Ro	NULL
(	NULL
SSA	NULL
)	NULL
and	NULL
anti-La	NULL
(	NULL
SSB	NULL
)	NULL
antibodies	NULL
against	NULL
bovine	NULL
spleen	NULL
extracts	NULL
relative	NULL
to	NULL
reference	NULL
sera	NULL
by	NULL
Ouchterlony	NULL
immuno-diffusion	NULL
and	NULL
counter	NULL
immunoelectrophoresis	NULL
(	NULL
19	NULL
,	NULL
24	NULL
)	NULL
.	NULL

Statistical	NULL
analysis	NULL
.	NULL

Statistical	NULL
analysis	NULL
of	NULL
RFLPs	NULL
was	NULL
carried	NULL
out	NULL
using	NULL
Fisher	NULL
's	NULL
exact	NULL
test	NULL
with	NULL
the	NULL
Epistat	NULL
software	NULL
package	NULL
for	NULL
PC-based	NULL
computer	NULL
systems	NULL
(	NULL
T.	NULL
Gustafson	NULL
,	NULL
Round	NULL
Rock	NULL
,	NULL
TX	NULL
)	NULL
.	NULL

The	NULL
chi-square	NULL
test	NULL
was	NULL
used	NULL
to	NULL
test	NULL
for	NULL
homogeneity	NULL
and	NULL
genotypic	NULL
differences	NULL
between	NULL
groups	NULL
.	NULL

Statistical	NULL
levels	NULL
of	NULL
confidence	NULL
are	NULL
shown	NULL
without	NULL
adjustment	NULL
for	NULL
the	NULL
number	NULL
of	NULL
comparisons	NULL
made	NULL
.	NULL

Results	NULL
In	NULL
preliminary	NULL
experiments	NULL
DNA	NULL
from	NULL
13	NULL
patients	NULL
was	NULL
digested	NULL
with	NULL
the	NULL
restriction	NULL
enzymes	NULL
Bgl	NULL
II	NULL
,	NULL
Eco	NULL
RI	NULL
,	NULL
Eco	NULL
RV	NULL
,	NULL
Hind	NULL
IH	NULL
,	NULL
Kpn	NULL
I	NULL
(	NULL
or	NULL
its	NULL
isoschizomer	NULL
Asp	NULL
718	NULL
)	NULL
,	NULL
Pst	NULL
I	NULL
,	NULL
Pvu	NULL
II	NULL
,	NULL
and	NULL
Taq	NULL
I.	NULL
Polymorphic	NULL
bands	NULL
hybridizing	NULL
to	NULL
the	NULL
human	NULL
TCR	NULL
probe	NULL
were	NULL
only	NULL
detected	NULL
after	NULL
digestion	NULL
with	NULL
Bgl	NULL
II	NULL
or	NULL
Kpn	NULL
I	NULL
.	NULL

The	NULL
paucity	NULL
of	NULL
RFLPs	NULL
in	NULL
these	NULL
patients	NULL
is	NULL
consistent	NULL
with	NULL
that	NULL
observed	NULL
in	NULL
a	NULL
previous	NULL
report	NULL
in	NULL
healthy	NULL
individuals	NULL
(	NULL
46	NULL
)	NULL
.	NULL

The	NULL
enzyme	NULL
Bgl	NULL
II	NULL
produced	NULL
9.8-	NULL
and	NULL
8.8-kb	NULL
polymorphic	NULL
fragments	NULL
and	NULL
a	NULL
1.2-kb	NULL
fragment	NULL
present	NULL
in	NULL
all	NULL
individuals	NULL
.	NULL

Digestion	NULL
with	NULL
Kpn	NULL
I	NULL
revealed	NULL
5.6-	NULL
and	NULL
1.7	NULL
5-kb	NULL
polymorphic	NULL
fragments	NULL
and	NULL
a	NULL
7.1-kb	NULL
constant	NULL
fragment	NULL
.	NULL

The	NULL
Bgl	NULL
II	NULL
RFLP	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
be	NULL
inherited	NULL
as	NULL
an	NULL
allelic	NULL
variant	NULL
(	NULL
39	NULL
,	NULL
46-48	NULL
)	NULL
.	NULL

Family	NULL
studies	NULL
in	NULL
our	NULL
laboratory	NULL
confirm	NULL
that	NULL
both	NULL
the	NULL
Bgl	NULL
II	NULL
and	NULL
Kpn	NULL
I	NULL
RFLPs	NULL
are	NULL
inherited	NULL
as	NULL
alleles	NULL
of	NULL
a	NULL
single	NULL
autosomal	NULL
locus	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

During	NULL
the	NULL
course	NULL
of	NULL
this	NULL
work	NULL
,	NULL
Oksenberg	NULL
et	NULL
al	NULL
.	NULL

(	NULL
47	NULL
)	NULL
reported	NULL
that	NULL
Kpn	NULL
I	NULL
RFLPs	NULL
similar	NULL
in	NULL
size	NULL
to	NULL
those	NULL
we	NULL
observed	NULL
were	NULL
inherited	NULL
as	NULL
alleles	NULL
in	NULL
three	NULL
families	NULL
.	NULL

The	NULL
location	NULL
of	NULL
the	NULL
polymorphic	NULL
Bgl	NULL
II	NULL
restriction	NULL
site	NULL
has	NULL
been	NULL
determined	NULL
(	NULL
46	NULL
,	NULL
48	NULL
,	NULL
49	NULL
)	NULL
.	NULL

Invariant	NULL
Bgl	NULL
II	NULL
sequences	NULL
are	NULL
present	NULL
in	NULL
the	NULL
first	NULL
exon	NULL
of	NULL
the	NULL
CS1	NULL
and	NULL
C2	NULL
genes	NULL
,	NULL
while	NULL
the	NULL
Bgl	NULL
II	NULL
site	NULL
678	NULL
nucleotides	NULL
5	NULL
'	NULL
of	NULL
the	NULL
CB2	NULL
invariant	NULL
site	NULL
is	NULL
poly-morphic	NULL
.	NULL

Therefore	NULL
,	NULL
the	NULL
Bgl	NULL
II	NULL
RFLPs	NULL
are	NULL
a	NULL
result	NULL
of	NULL
hybridization	NULL
of	NULL
the	NULL
TCR	NULL
C	NULL
#	NULL
probe	NULL
to	NULL
the	NULL
CS1	NULL
gene	NULL
.	NULL

To	NULL
determine	NULL
the	NULL
location	NULL
of	NULL
the	NULL
Kpn	NULL
I	NULL
polymorphic	NULL
site	NULL
we	NULL
initially	NULL
searched	NULL
a	NULL
computer	NULL
data	NULL
base	NULL
for	NULL
human	NULL
TCR	NULL
nucleotide	NULL
sequences	NULL
and	NULL
located	NULL
Kpn	NULL
I	NULL
sites	NULL
between	NULL
the	NULL
second	NULL
and	NULL
third	NULL
exons	NULL
of	NULL
the	NULL
CB1	NULL
and	NULL
C82	NULL
genes	NULL
(	NULL
49	NULL
)	NULL
.	NULL

A	NULL
third	NULL
Kpn	NULL
I	NULL
site	NULL
was	NULL
found	NULL
1.8	NULL
kb	NULL
5	NULL
'	NULL
of	NULL
the	NULL
Kpn	NULL
I	NULL
sequence	NULL
in	NULL
the	NULL
intron	NULL
of	NULL
the	NULL
CB2	NULL
,	NULL
but	NULL
not	NULL
the	NULL
C31	NULL
gene	NULL
.	NULL

Because	NULL
this	NULL
is	NULL
similar	NULL
in	NULL
size	NULL
to	NULL
one	NULL
of	NULL
the	NULL
Kpn	NULL
I	NULL
RFLPs	NULL
we	NULL
observed	NULL
,	NULL
we	NULL
used	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
polymorphic	NULL
Bgl	NULL
II	NULL
site	NULL
in	NULL
this	NULL
region	NULL
to	NULL
test	NULL
the	NULL
hypothesis	NULL
that	NULL
the	NULL
Kpn	NULL
I	NULL
RFLPs	NULL
are	NULL
due	NULL
to	NULL
hybridization	NULL
of	NULL
the	NULL
TCR	NULL
CB	NULL
probe	NULL
to	NULL
the	NULL
CB2	NULL
gene	NULL
.	NULL

Double	NULL
digestions	NULL
using	NULL
Kpn	NULL
I	NULL
and	NULL
Bgl	NULL
II	NULL
produced	NULL
three	NULL
fragment	NULL
sizes	NULL
.	NULL

A	NULL
0.91-kb	NULL
fragment	NULL
was	NULL
detected	NULL
in	NULL
everyone	NULL
and	NULL
corresponded	NULL
to	NULL
the	NULL
probe	NULL
hybridizing	NULL
to	NULL
the	NULL
C	NULL
#	NULL
I1	NULL
gene	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
.	NULL

The	NULL
polymorphic	NULL
0.98-	NULL
and	NULL
1.05-kb	NULL
fragments	NULL
found	NULL
in	NULL
individuals	NULL
with	NULL
the	NULL
Kpn	NULL
I	NULL
1.75-	NULL
and	NULL
5.6-kb	NULL
RFLPs	NULL
,	NULL
respectively	NULL
,	NULL
were	NULL
as	NULL
predicted	NULL
if	NULL
the	NULL
polymorphic	NULL
Kpn	NULL
I	NULL
site	NULL
occurs	NULL
between	NULL
the	NULL
second	NULL
and	NULL
third	NULL
CS2	NULL
exon	NULL
.	NULL

Because	NULL
the	NULL
TCR	NULL
CS	NULL
probe	NULL
used	NULL
lacked	NULL
the	NULL
fourth	NULL
and	NULL
nearly	NULL
all	NULL
of	NULL
the	NULL
£	NULL
0.904	NULL
ro.or	NULL
i-1.05-1	NULL
B	NULL
K	NULL
KB	NULL
's	NULL
k	NULL
's	NULL
K	NULL
_	NULL
H	NULL
__|	NULL
I1	NULL
|	NULL
i	NULL
a	NULL
``	NULL
``	NULL
mmr	NULL
?	NULL

``	NULL
rey	NULL
ger	NULL
csi	NULL
Dp2	NULL
ug2	NULL
cp2	NULL
isp	NULL
L_LJ	NULL
I	NULL
Kpn	NULL
RFLPs	NULL
5.60	NULL
Pn	NULL
l	NULL
8.8	NULL
kb	NULL
Bal	NULL
II	NULL
RFLP	NULL
f	NULL
9.8	NULL
kb	NULL
Bgl	NULL
II	NULL
RFLP	NULL
!	NULL

j	NULL
1	NULL
Figure	NULL
1	NULL
.	NULL

Restriction	NULL
enzyme	NULL
map	NULL
of	NULL
the	NULL
Bgl	NULL
II	NULL
and	NULL
Kpn	NULL
I	NULL
recognition	NULL
sites	NULL
in	NULL
the	NULL
TCR	NULL
CS	NULL
loci	NULL
.	NULL

Exon	NULL
positions	NULL
are	NULL
indicated	NULL
below	NULL
the	NULL
horizontal	NULL
line	NULL
and	NULL
restriction	NULL
enzyme	NULL
sites	NULL
above	NULL
the	NULL
line	NULL
.	NULL

B	NULL
,	NULL
Bg	NULL
!	NULL

II	NULL
site	NULL
;	NULL
K	NULL
,	NULL
Kpn	NULL
I	NULL
site	NULL
.	NULL

B	NULL
'	NULL
and	NULL
K	NULL
'	NULL
indicate	NULL
positions	NULL
of	NULL
polymorphic	NULL
sites	NULL
for	NULL
the	NULL
Bgl	NULL
II	NULL
and	NULL
Kpn	NULL
I	NULL
enzymes	NULL
,	NULL
respectively	NULL
.	NULL

Molecular	NULL
sizes	NULL
of	NULL
TCR	NULL
CS	NULL
polymorphic	NULL
fragments	NULL
after	NULL
double	NULL
digestion	NULL
with	NULL
both	NULL
enzymes	NULL
are	NULL
shown	NULL
at	NULL
the	NULL
top	NULL
of	NULL
the	NULL
figure	NULL
.	NULL

third	NULL
constant	NULL
region	NULL
exons	NULL
,	NULL
no	NULL
hybridization	NULL
was	NULL
detected	NULL
after	NULL
Kpn	NULL
I	NULL
digestion	NULL
with	NULL
DNA	NULL
3	NULL
'	NULL
of	NULL
the	NULL
C81	NULL
Kpn	NULL
I	NULL
site	NULL
or	NULL
with	NULL
the	NULL
homologous	NULL
portions	NULL
of	NULL
the	NULL
CS2	NULL
gene	NULL
in	NULL
individuals	NULL
with	NULL
the	NULL
1.75-kb	NULL
Kpn	NULL
I	NULL
RFLP	NULL
.	NULL

Therefore	NULL
,	NULL
while	NULL
the	NULL
Bgl	NULL
II	NULL
RFLPs	NULL
were	NULL
detected	NULL
by	NULL
hybridization	NULL
of	NULL
the	NULL
probe	NULL
with	NULL
the	NULL
CB1	NULL
gene	NULL
,	NULL
the	NULL
Kpn	NULL
I	NULL
RFLPs	NULL
were	NULL
due	NULL
to	NULL
hybridization	NULL
with	NULL
the	NULL
C	NULL
#	NULL
2	NULL
gene	NULL
.	NULL

This	NULL
suggests	NULL
that	NULL
combinations	NULL
of	NULL
these	NULL
RFLPs	NULL
may	NULL
be	NULL
useful	NULL
as	NULL
markers	NULL
for	NULL
an	NULL
extended	NULL
region	NULL
of	NULL
this	NULL
portion	NULL
of	NULL
the	NULL
ge-nome	NULL
,	NULL
which	NULL
includes	NULL
not	NULL
only	NULL
exons	NULL
coding	NULL
for	NULL
constant	NULL
portions	NULL
of	NULL
T	NULL
cell	NULL
receptor	NULL
polypeptides	NULL
,	NULL
but	NULL
for	NULL
variable	NULL
regions	NULL
(	NULL
D8	NULL
and	NULL
J8	NULL
)	NULL
as	NULL
well	NULL
.	NULL

Because	NULL
strong	NULL
associations	NULL
between	NULL
HLA	NULL
class	NULL
II	NULL
region	NULL
markers	NULL
and	NULL
anti-Ro	NULL
(	NULL
SSA	NULL
)	NULL
antibodies	NULL
have	NULL
been	NULL
described	NULL
in	NULL
lupus	NULL
patients	NULL
,	NULL
we	NULL
wished	NULL
to	NULL
determine	NULL
if	NULL
the	NULL
markers	NULL
for	NULL
the	NULL
TCR	NULL
genes	NULL
we	NULL
identified	NULL
might	NULL
be	NULL
useful	NULL
in	NULL
detecting	NULL
associations	NULL
between	NULL
TCR	NULL
genes	NULL
and	NULL
the	NULL
anti-Ro	NULL
(	NULL
SSA	NULL
)	NULL
response	NULL
.	NULL

An	NULL
increase	NULL
in	NULL
the	NULL
allelic	NULL
frequency	NULL
of	NULL
the	NULL
Bgl	NULL
II	NULL
9.8-kb	NULL
(	NULL
P	NULL
=	NULL
0.05	NULL
)	NULL
as	NULL
well	NULL
as	NULL
the	NULL
Kpn	NULL
I	NULL
1.75-kb	NULL
(	NULL
P	NULL
=	NULL
0.05	NULL
)	NULL
RFLP	NULL
was	NULL
found	NULL
in	NULL
the	NULL
42	NULL
patients	NULL
with	NULL
the	NULL
Ro	NULL
(	NULL
SSA	NULL
)	NULL
precipitin	NULL
when	NULL
compared	NULL
with	NULL
the	NULL
34	NULL
patients	NULL
who	NULL
lacked	NULL
this	NULL
precipitin	NULL
(	NULL
Table	NULL
I	NULL
)	NULL
.	NULL

Genotypi-	NULL
Table	NULL
I.	NULL
Allele	NULL
and	NULL
Genotype	NULL
Distributions	NULL
of	NULL
TCR	NULL
CB	NULL
RFLPs	NULL
Table	NULL
II	NULL
.	NULL

Combination	NULL
of	NULL
Bgl	NULL
II	NULL
9.8-kb	NULL
RFLP	NULL
and	NULL
Kpn	NULL
I	NULL
1.75-kb	NULL
RFLP	NULL
RFLP	NULL
combination	NULL
Anti-Ro	NULL
Present	NULL
Absent	NULL
Total	NULL
P	NULL
+	NULL
32	NULL
10	NULL
42	NULL
--	NULL
14	NULL
20	NULL
34	NULL
0.002	NULL
The	NULL
number	NULL
of	NULL
individuals	NULL
in	NULL
which	NULL
the	NULL
RFLP	NULL
pair	NULL
is	NULL
present	NULL
or	NULL
absent	NULL
is	NULL
shown	NULL
for	NULL
each	NULL
group	NULL
.	NULL

P	NULL
values	NULL
were	NULL
calculated	NULL
using	NULL
Fisher	NULL
's	NULL
exact	NULL
test	NULL
.	NULL

cally	NULL
,	NULL
Bgl	NULL
II	NULL
9.8-kb	NULL
homozygotes	NULL
occurred	NULL
more	NULL
frequently	NULL
in	NULL
the	NULL
Ro	NULL
(	NULL
SSA	NULL
)	NULL
precipitin-positive	NULL
group	NULL
(	NULL
P	NULL
=	NULL
0.02	NULL
)	NULL
.	NULL

However	NULL
,	NULL
these	NULL
differences	NULL
were	NULL
not	NULL
statistically	NULL
significant	NULL
after	NULL
multiplying	NULL
the	NULL
probability	NULL
values	NULL
by	NULL
the	NULL
number	NULL
of	NULL
comparisons	NULL
made	NULL
.	NULL

When	NULL
analyzed	NULL
together	NULL
,	NULL
the	NULL
Bgl	NULL
II	NULL
and	NULL
Kpn	NULL
I	NULL
RFLPs	NULL
may	NULL
act	NULL
as	NULL
a	NULL
marker	NULL
for	NULL
an	NULL
extended	NULL
region	NULL
of	NULL
the	NULL
TCR	NULL
locus	NULL
,	NULL
and	NULL
otherwise	NULL
identify	NULL
genes	NULL
that	NULL
are	NULL
important	NULL
in	NULL
the	NULL
recognition	NULL
of	NULL
the	NULL
Ro	NULL
(	NULL
SSA	NULL
)	NULL
autoantigen	NULL
.	NULL

Consistent	NULL
with	NULL
this	NULL
hypothesis	NULL
,	NULL
we	NULL
noted	NULL
that	NULL
32	NULL
of	NULL
the	NULL
37	NULL
patients	NULL
with	NULL
the	NULL
Ro	NULL
(	NULL
SSA	NULL
)	NULL
precipitin	NULL
who	NULL
had	NULL
the	NULL
Bgl	NULL
II	NULL
9.8-kb	NULL
RFLP	NULL
(	NULL
Table	NULL
I	NULL
)	NULL
also	NULL
had	NULL
the	NULL
Kpn	NULL
I	NULL
1.75-kb	NULL
RFLP	NULL
.	NULL

Table	NULL
II	NULL
shows	NULL
that	NULL
the	NULL
combination	NULL
of	NULL
these	NULL
two	NULL
RFLPs	NULL
was	NULL
present	NULL
in	NULL
76	NULL
%	NULL
of	NULL
the	NULL
patients	NULL
with	NULL
Ro	NULL
(	NULL
SSA	NULL
)	NULL
precipitins	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
it	NULL
occurred	NULL
in	NULL
only	NULL
14	NULL
of	NULL
34	NULL
patients	NULL
(	NULL
41	NULL
%	NULL
)	NULL
lacking	NULL
this	NULL
precipitin	NULL
,	NULL
resulting	NULL
in	NULL
a	NULL
highly	NULL
significant	NULL
difference	NULL
between	NULL
these	NULL
two	NULL
patient	NULL
groups	NULL
(	NULL
P	NULL
=	NULL
0.002	NULL
)	NULL
.	NULL

When	NULL
all	NULL
76	NULL
lupus	NULL
patients	NULL
were	NULL
considered	NULL
as	NULL
a	NULL
single	NULL
group	NULL
,	NULL
the	NULL
frequency	NULL
of	NULL
these	NULL
two	NULL
Bgl	NULL
II	NULL
and	NULL
Kpn	NULL
I	NULL
RFLPs	NULL
did	NULL
not	NULL
differ	NULL
from	NULL
that	NULL
found	NULL
in	NULL
25	NULL
healthy	NULL
subjects	NULL
(	NULL
Table	NULL
III	NULL
)	NULL
.	NULL

These	NULL
results	NULL
are	NULL
consistent	NULL
with	NULL
those	NULL
of	NULL
others	NULL
who	NULL
have	NULL
failed	NULL
to	NULL
find	NULL
differences	NULL
when	NULL
comparing	NULL
the	NULL
Bgl	NULL
II	NULL
RFLPs	NULL
between	NULL
SLE	NULL
patients	NULL
and	NULL
controls	NULL
(	NULL
37-39	NULL
)	NULL
.	NULL

The	NULL
joint	NULL
occurrence	NULL
of	NULL
these	NULL
two	NULL
RFLPs	NULL
does	NULL
not	NULL
,	NULL
therefore	NULL
,	NULL
appear	NULL
to	NULL
be	NULL
a	NULL
risk	NULL
factor	NULL
for	NULL
the	NULL
disease	NULL
.	NULL

Rather	NULL
,	NULL
the	NULL
RFLP	NULL
combination	NULL
is	NULL
a	NULL
marker	NULL
for	NULL
TCR	NULL
#	NULL
genes	NULL
involved	NULL
in	NULL
the	NULL
production	NULL
of	NULL
anti-Ro	NULL
(	NULL
SSA	NULL
)	NULL
antibodies	NULL
in	NULL
a	NULL
subset	NULL
of	NULL
lupus	NULL
patients	NULL
(	NULL
Table	NULL
III	NULL
)	NULL
.	NULL

We	NULL
have	NULL
initiated	NULL
experiments	NULL
to	NULL
determine	NULL
whether	NULL
the	NULL
Bgl	NULL
II	NULL
9.8-	NULL
and	NULL
Kpn	NULL
I	NULL
1.75-kb	NULL
markers	NULL
preferentially	NULL
occur	NULL
on	NULL
the	NULL
same	NULL
chromosome	NULL
in	NULL
lupus	NULL
patients	NULL
with	NULL
the	NULL
anti-Ro	NULL
(	NULL
SSA	NULL
)	NULL
Allelic	NULL
distributi	NULL
has	NULL
.	NULL

.	NULL

``	NULL
C	NULL
uuons	NULL
precipitins	NULL
.	NULL

Of	NULL
the	NULL
Ro	NULL
(	NULL
SSA	NULL
)	NULL
precipitin-positive	NULL
patients	NULL
studied	NULL
Patients	NULL
with	NULL
Bel	NULL
II	NULL
Patients	NULL
with	NULL
with	NULL
both	NULL
of	NULL
these	NULL
RFLPs	NULL
,	NULL
the	NULL
linkage	NULL
phase	NULL
of	NULL
these	NULL
markers	NULL
is	NULL
alleles	NULL
Kpn	NULL
I	NULL
alleles	NULL
in	NULL
coupling	NULL
(	NULL
i.e	NULL
.	NULL

,	NULL
on	NULL
the	NULL
same	NULL
chromosome	NULL
)	NULL
in	NULL
24	NULL
patients	NULL
,	NULL
and	NULL
Group	NULL
9.8	NULL
8.8	NULL
5.6	NULL
1.7	NULL
;	NULL
__	NULL
in	NULL
repulsion	NULL
(	NULL
i.e	NULL
.	NULL

,	NULL
opposite	NULL
chromosomes	NULL
)	NULL
in	NULL
only	NULL
2	NULL
patients	NULL
.	NULL

However	NULL
,	NULL
these	NULL
markers	NULL
also	NULL
occur	NULL
on	NULL
the	NULL
same	NULL
chromosome	NULL
Ro+	NULL
37	NULL
23	NULL
24	NULL
36	NULL
Ro-	NULL
24	NULL
27	NULL
21	NULL
23	NULL
Table	NULL
III	NULL
.	NULL

Combination	NULL
of	NULL
Bgl	NULL
II	NULL
9.8-kb	NULL
RFLP	NULL
Genotypic	NULL
distributions	NULL
and	NULL
Kpn	NULL
I	NULL
1.75-kb	NULL
RFLP	NULL
Bgi	NULL
II	NULL
Kpn	NULL
I	NULL
RFLP	NULL
combination	NULL
Group	NULL
9.8/9.8	NULL
9.8/8.8	NULL
8.8/8.8	NULL
5.6/5.6	NULL
5.6/1.75	NULL
1.75/1.75	NULL
Group	NULL
Present	NULL
Absent	NULL
Total	NULL
P	NULL
Ro+	NULL
19	NULL
18	NULL
5	NULL
6	NULL
18	NULL
18	NULL
SLE	NULL
patients	NULL
46	NULL
30	NULL
76	NULL
-Ro-	NULL
7	NULL
17	NULL
10	NULL
11	NULL
10	NULL
13	NULL
Healthy	NULL
subjects	NULL
13	NULL
12	NULL
25	NULL
0.30	NULL
The	NULL
numbers	NULL
of	NULL
patients	NULL
with	NULL
each	NULL
allele	NULL
and	NULL
genotype	NULL
in	NULL
each	NULL
group	NULL
are	NULL
shown	NULL
.	NULL

The	NULL
total	NULL
number	NULL
of	NULL
individuals	NULL
in	NULL
the	NULL
Ro+	NULL
and	NULL
Ro	NULL
groups	NULL
are	NULL
42	NULL
and	NULL
34	NULL
,	NULL
respectively	NULL
.	NULL

The	NULL
number	NULL
of	NULL
individuals	NULL
in	NULL
which	NULL
the	NULL
RFLP	NULL
pair	NULL
is	NULL
present	NULL
or	NULL
absent	NULL
is	NULL
shown	NULL
for	NULL
each	NULL
group	NULL
.	NULL

P	NULL
values	NULL
were	NULL
calculated	NULL
using	NULL
Fisher	NULL
's	NULL
exact	NULL
test	NULL
.	NULL

T	NULL
Cell	NULL
Receptor	NULL
Genes	NULL
and	NULL
Anti-Ro	NULL
(	NULL
SSA	NULL
)	NULL
Antibodies	NULL
in	NULL
Systemic	NULL
Lupus	NULL
Erythematosus	NULL
-_	NULL
35	NULL
in	NULL
9	NULL
of	NULL
the	NULL
15	NULL
Ro	NULL
(	NULL
SSA	NULL
)	NULL
precipitin-negative	NULL
patients	NULL
that	NULL
we	NULL
have	NULL
studied	NULL
.	NULL

Fully	NULL
informative	NULL
pedigrees	NULL
must	NULL
be	NULL
analyzed	NULL
from	NULL
additional	NULL
patients	NULL
before	NULL
definitive	NULL
results	NULL
can	NULL
be	NULL
reached	NULL
on	NULL
this	NULL
issue	NULL
.	NULL

However	NULL
,	NULL
these	NULL
findings	NULL
suggest	NULL
that	NULL
the	NULL
mere	NULL
presence	NULL
of	NULL
these	NULL
RFLPs	NULL
on	NULL
the	NULL
same	NULL
chromosome	NULL
is	NULL
not	NULL
sufficient	NULL
for	NULL
production	NULL
of	NULL
the	NULL
anti-Ro	NULL
(	NULL
SSA	NULL
)	NULL
antibodies	NULL
in	NULL
lupus	NULL
patients	NULL
.	NULL

Detection	NULL
of	NULL
a	NULL
functional	NULL
exon	NULL
that	NULL
codes	NULL
for	NULL
a	NULL
TCR	NULL
polypeptide	NULL
recognizing	NULL
the	NULL
Ro	NULL
(	NULL
SSA	NULL
)	NULL
autoantigen	NULL
will	NULL
be	NULL
required	NULL
to	NULL
determine	NULL
whether	NULL
these	NULL
two	NULL
RFLP	NULL
markers	NULL
are	NULL
in	NULL
linkage	NULL
disequilibrium	NULL
with	NULL
such	NULL
a	NULL
gene	NULL
.	NULL

As	NULL
discussed	NULL
in	NULL
the	NULL
introduction	NULL
,	NULL
patients	NULL
with	NULL
the	NULL
Ro	NULL
(	NULL
SSA	NULL
)	NULL
precipitin	NULL
differ	NULL
genetically	NULL
at	NULL
HLA	NULL
loci	NULL
and	NULL
clinically	NULL
from	NULL
patients	NULL
with	NULL
both	NULL
the	NULL
Ro	NULL
(	NULL
SSA	NULL
)	NULL
and	NULL
La	NULL
(	NULL
SSB	NULL
)	NULL
precipitins	NULL
.	NULL

We	NULL
have	NULL
,	NULL
therefore	NULL
,	NULL
divided	NULL
the	NULL
Ro	NULL
(	NULL
SSA	NULL
)	NULL
-positive	NULL
patients	NULL
into	NULL
two	NULL
groups	NULL
based	NULL
on	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
La	NULL
(	NULL
SSB	NULL
)	NULL
precipitins	NULL
.	NULL

A	NULL
homogeneity	NULL
chi-square	NULL
test	NULL
of	NULL
the	NULL
combined	NULL
presence	NULL
of	NULL
the	NULL
Bg	NULL
!	NULL

II	NULL
9.8-	NULL
and	NULL
Kpn	NULL
I	NULL
1.75-kb	NULL
RFLPs	NULL
revealed	NULL
significant	NULL
differences	NULL
between	NULL
these	NULL
two	NULL
patient	NULL
subsets	NULL
(	NULL
P	NULL
<	NULL
0.05	NULL
)	NULL
,	NULL
suggesting	NULL
on	NULL
the	NULL
basis	NULL
of	NULL
these	NULL
RFLPs	NULL
that	NULL
patients	NULL
in	NULL
these	NULL
groups	NULL
should	NULL
not	NULL
be	NULL
pooled	NULL
.	NULL

As	NULL
expected	NULL
in	NULL
a	NULL
cohort	NULL
of	NULL
this	NULL
size	NULL
(	NULL
76	NULL
patients	NULL
)	NULL
,	NULL
the	NULL
number	NULL
of	NULL
patients	NULL
with	NULL
both	NULL
precipitins	NULL
is	NULL
small	NULL
,	NULL
and	NULL
therefore	NULL
conclusions	NULL
regarding	NULL
this	NULL
particular	NULL
subgroup	NULL
should	NULL
be	NULL
considered	NULL
tentative	NULL
.	NULL

Table	NULL
IV	NULL
shows	NULL
that	NULL
the	NULL
proportion	NULL
of	NULL
patients	NULL
with	NULL
Ro	NULL
(	NULL
SSA	NULL
)	NULL
and	NULL
La	NULL
(	NULL
SSB	NULL
)	NULL
precipitins	NULL
who	NULL
have	NULL
both	NULL
the	NULL
Bgl	NULL
II	NULL
9.8-	NULL
and	NULL
Kpn	NULL
I	NULL
1.75-kb	NULL
RFLPs	NULL
is	NULL
more	NULL
similar	NULL
to	NULL
that	NULL
found	NULL
in	NULL
patients	NULL
lacking	NULL
the	NULL
Ro	NULL
(	NULL
SSA	NULL
)	NULL
precipitin	NULL
(	NULL
P	NULL
=	NULL
0.33	NULL
)	NULL
than	NULL
to	NULL
patients	NULL
with	NULL
just	NULL
the	NULL
Ro	NULL
(	NULL
SSA	NULL
)	NULL
precipitin	NULL
(	NULL
P	NULL
=	NULL
0.06	NULL
)	NULL
.	NULL

These	NULL
two	NULL
RFLPs	NULL
occur	NULL
in	NULL
84	NULL
%	NULL
of	NULL
the	NULL
patients	NULL
with	NULL
only	NULL
the	NULL
Ro	NULL
(	NULL
SSA	NULL
)	NULL
precipitin	NULL
,	NULL
thus	NULL
reducing	NULL
the	NULL
probability	NULL
eightfold	NULL
(	NULL
P	NULL
=	NULL
0.0004	NULL
)	NULL
compared	NULL
with	NULL
that	NULL
observed	NULL
when	NULL
Ro	NULL
(	NULL
SSA	NULL
)	NULL
-positive	NULL
and	NULL
-negative	NULL
patients	NULL
,	NULL
irrespective	NULL
of	NULL
their	NULL
La	NULL
(	NULL
SSB	NULL
)	NULL
precipitin	NULL
status	NULL
were	NULL
analyzed	NULL
above	NULL
.	NULL

Of	NULL
the	NULL
32	NULL
Ro	NULL
(	NULL
SSA	NULL
)	NULL
precipitin-positive	NULL
patients	NULL
with	NULL
both	NULL
of	NULL
these	NULL
RFLPs	NULL
,	NULL
26	NULL
of	NULL
them	NULL
lacked	NULL
La	NULL
(	NULL
SSB	NULL
)	NULL
precipitins	NULL
.	NULL

Due	NULL
to	NULL
sample	NULL
size	NULL
,	NULL
these	NULL
findings	NULL
suggest	NULL
,	NULL
but	NULL
do	NULL
not	NULL
prove	NULL
,	NULL
that	NULL
the	NULL
group	NULL
of	NULL
Ro	NULL
(	NULL
SSA	NULL
)	NULL
precipitin-positive	NULL
patients	NULL
lacking	NULL
La	NULL
(	NULL
SSB	NULL
)	NULL
precipitins	NULL
are	NULL
responsible	NULL
for	NULL
the	NULL
differences	NULL
between	NULL
the	NULL
Ro	NULL
(	NULL
SSA	NULL
)	NULL
precipitin-positive	NULL
and	NULL
-negative	NULL
patients	NULL
.	NULL

High	NULL
titers	NULL
of	NULL
anti-Ro	NULL
(	NULL
SSA	NULL
)	NULL
antibodies	NULL
have	NULL
previously	NULL
been	NULL
described	NULL
in	NULL
HLA-DQ1/DQ2	NULL
heterozygous	NULL
patients	NULL
with	NULL
primary	NULL
Sjogren	NULL
's	NULL
syndrome	NULL
and	NULL
SLE	NULL
(	NULL
14	NULL
,	NULL
17	NULL
)	NULL
.	NULL

In	NULL
this	NULL
patient	NULL
cohort	NULL
,	NULL
11	NULL
of	NULL
the	NULL
26	NULL
(	NULL
42	NULL
%	NULL
)	NULL
HLA	NULL
typed	NULL
patients	NULL
with	NULL
only	NULL
the	NULL
anti-Ro	NULL
(	NULL
SSA	NULL
)	NULL
precipitin	NULL
are	NULL
HLA-DQ1/DQ2	NULL
heterozygotes	NULL
,	NULL
compared	NULL
with	NULL
only	NULL
2	NULL
of	NULL
22	NULL
(	NULL
9	NULL
%	NULL
)	NULL
HLA-DQ	NULL
typed	NULL
anti-Ro	NULL
(	NULL
SSA	NULL
)	NULL
-negative	NULL
patients	NULL
(	NULL
P	NULL
=	NULL
0.01	NULL
)	NULL
.	NULL

If	NULL
the	NULL
TCR	NULL
RFLPs	NULL
are	NULL
indeed	NULL
markers	NULL
for	NULL
functional	NULL
genes	NULL
that	NULL
recognize	NULL
the	NULL
Table	NULL
IV	NULL
.	NULL

Combination	NULL
of	NULL
Bel	NULL
II	NULL
9.8-kb	NULL
RFLP	NULL
and	NULL
Kpn	NULL
I	NULL
1.75-kb	NULL
RFLP	NULL
Precipitin	NULL
RFLP	NULL
combination	NULL
Anti-Ro	NULL
Anti-La	NULL
Present	NULL
Absent	NULL
Total	NULL
P	NULL
-	NULL
-	NULL
14	NULL
20	NULL
34	NULL
+	NULL
-	NULL
26	NULL
5	NULL
31	NULL
0.0004	NULL
+	NULL
+	NULL
6	NULL
5	NULL
11	NULL
0.33	NULL
The	NULL
number	NULL
of	NULL
individuals	NULL
in	NULL
which	NULL
the	NULL
RFLP	NULL
combination	NULL
is	NULL
present	NULL
or	NULL
absent	NULL
is	NULL
shown	NULL
for	NULL
each	NULL
group	NULL
.	NULL

P	NULL
values	NULL
were	NULL
calculated	NULL
using	NULL
Fisher	NULL
's	NULL
exact	NULL
test	NULL
when	NULL
compared	NULL
with	NULL
the	NULL
Ro	NULL
(	NULL
SSA	NULL
)	NULL
precipitin-negative	NULL
patients	NULL
.	NULL

36	NULL
-	NULL
M.	NULL
B.	NULL
Frank	NULL
,	NULL
R.	NULL
McArthur	NULL
,	NULL
J	NULL
.	NULL

B.	NULL
Harley	NULL
,	NULL
and	NULL
A.	NULL
Fujisaku	NULL
Ro	NULL
(	NULL
SSA	NULL
)	NULL
antigen	NULL
in	NULL
conjunction	NULL
with	NULL
HLA	NULL
class	NULL
II	NULL
molecules	NULL
,	NULL
one	NULL
would	NULL
expect	NULL
to	NULL
find	NULL
an	NULL
association	NULL
between	NULL
these	NULL
TCR	NULL
markers	NULL
and	NULL
these	NULL
HLA-DQ	NULL
antigens	NULL
in	NULL
Ro	NULL
(	NULL
SSA	NULL
)	NULL
precipitin-positive	NULL
but	NULL
not	NULL
-negative	NULL
patients	NULL
.	NULL

The	NULL
Ro	NULL
(	NULL
SSA	NULL
)	NULL
precipitin	NULL
was	NULL
found	NULL
in	NULL
20	NULL
of	NULL
24	NULL
patients	NULL
(	NULL
83	NULL
%	NULL
)	NULL
with	NULL
the	NULL
HLA-DQ	NULL
antigen	NULL
who	NULL
also	NULL
had	NULL
the	NULL
TCR	NULL
RFLP	NULL
markers	NULL
,	NULL
but	NULL
in	NULL
only	NULL
4	NULL
of	NULL
the	NULL
Ro	NULL
(	NULL
SSA	NULL
)	NULL
precipitin-negative	NULL
patients	NULL
with	NULL
these	NULL
markers	NULL
(	NULL
P	NULL
=	NULL
0.004	NULL
)	NULL
.	NULL

The	NULL
DQ2	NULL
serotype	NULL
(	NULL
P	NULL
=	NULL
0.065	NULL
)	NULL
and	NULL
DQ1/DQ2	NULL
heterozygosity	NULL
(	NULL
P	NULL
=	NULL
0.013	NULL
)	NULL
were	NULL
less	NULL
strongly	NULL
associated	NULL
with	NULL
these	NULL
markers	NULL
.	NULL

The	NULL
frequency	NULL
of	NULL
the	NULL
joint	NULL
occurrence	NULL
of	NULL
the	NULL
HLA-DQ1	NULL
serotype	NULL
and	NULL
the	NULL
TCR	NULL
#	NULL
RFLPs	NULL
in	NULL
healthy	NULL
individuals	NULL
was	NULL
similar	NULL
to	NULL
that	NULL
in	NULL
the	NULL
Ro	NULL
(	NULL
SSA	NULL
)	NULL
precipitin-negative	NULL
patients	NULL
(	NULL
P	NULL
=	NULL
0.39	NULL
)	NULL
.	NULL

An	NULL
association	NULL
of	NULL
this	NULL
nature	NULL
is	NULL
not	NULL
expected	NULL
if	NULL
the	NULL
TCRB	NULL
RFLPs	NULL
are	NULL
not	NULL
markers	NULL
for	NULL
a	NULL
functional	NULL
TCR	NULL
gene	NULL
or	NULL
regulatory	NULL
element	NULL
involved	NULL
in	NULL
TCR	NULL
gene	NULL
ex-pression	NULL
.	NULL

These	NULL
studies	NULL
suggest	NULL
the	NULL
existence	NULL
of	NULL
a	NULL
multigenic	NULL
interaction	NULL
between	NULL
products	NULL
of	NULL
these	NULL
loci	NULL
in	NULL
the	NULL
generation	NULL
of	NULL
anti-Ro	NULL
(	NULL
SSA	NULL
)	NULL
antibodies	NULL
.	NULL

Discussion	NULL
In	NULL
this	NULL
study	NULL
we	NULL
identified	NULL
TCRB	NULL
RFLPs	NULL
that	NULL
occur	NULL
in	NULL
a	NULL
disproportionately	NULL
high	NULL
frequency	NULL
in	NULL
a	NULL
subset	NULL
of	NULL
SLE	NULL
patients	NULL
with	NULL
anti-Ro	NULL
(	NULL
SSA	NULL
)	NULL
antibodies	NULL
.	NULL

The	NULL
majority	NULL
of	NULL
these	NULL
patients	NULL
lack	NULL
anti-La	NULL
(	NULL
SSB	NULL
)	NULL
antibodies	NULL
.	NULL

Since	NULL
no	NULL
differences	NULL
were	NULL
found	NULL
with	NULL
respect	NULL
to	NULL
these	NULL
RFLPs	NULL
between	NULL
patients	NULL
when	NULL
considered	NULL
as	NULL
a	NULL
single	NULL
group	NULL
and	NULL
healthy	NULL
subjects	NULL
,	NULL
these	NULL
RFLPs	NULL
appear	NULL
to	NULL
be	NULL
markers	NULL
for	NULL
the	NULL
production	NULL
of	NULL
specific	NULL
autoantibodies	NULL
in	NULL
lupus	NULL
rather	NULL
than	NULL
risk	NULL
factors	NULL
for	NULL
the	NULL
disease	NULL
.	NULL

In	NULL
studies	NULL
by	NULL
others	NULL
the	NULL
presence	NULL
of	NULL
Ro	NULL
{	NULL
(	NULL
SSA	NULL
)	NULL
and	NULL
La	NULL
(	NULL
SSB	NULL
)	NULL
precipitins	NULL
has	NULL
been	NULL
associated	NULL
with	NULL
clinical	NULL
and	NULL
genetic	NULL
differences	NULL
among	NULL
lupus	NULL
patients	NULL
(	NULL
11	NULL
,	NULL
15	NULL
,	NULL
17	NULL
,	NULL
24-26	NULL
)	NULL
.	NULL

Given	NULL
findings	NULL
of	NULL
the	NULL
pathophysio-logic	NULL
significance	NULL
of	NULL
anti-Ro	NULL
(	NULL
SSA	NULL
)	NULL
antibodies	NULL
in	NULL
lupus	NULL
,	NULL
these	NULL
results	NULL
suggest	NULL
a	NULL
role	NULL
for	NULL
TCR	NULL
genes	NULL
in	NULL
the	NULL
disease	NULL
process	NULL
.	NULL

Five	NULL
patients	NULL
who	NULL
make	NULL
only	NULL
anti-Ro	NULL
antibodies	NULL
lack	NULL
the	NULL
Bgl	NULL
II	NULL
9.8-	NULL
and	NULL
Kpn	NULL
I	NULL
1.75-kb	NULL
RFLPs	NULL
.	NULL

This	NULL
finding	NULL
and	NULL
the	NULL
observation	NULL
that	NULL
this	NULL
RFLP	NULL
combination	NULL
is	NULL
present	NULL
in	NULL
nearly	NULL
half	NULL
of	NULL
all	NULL
participants	NULL
without	NULL
detectable	NULL
levels	NULL
of	NULL
anti-Ro	NULL
(	NULL
SSA	NULL
)	NULL
antibodies	NULL
suggest	NULL
that	NULL
the	NULL
RFLP	NULL
markers	NULL
themselves	NULL
are	NULL
neither	NULL
necessary	NULL
nor	NULL
sufficient	NULL
for	NULL
the	NULL
anti-Ro	NULL
(	NULL
SSA	NULL
)	NULL
response	NULL
.	NULL

This	NULL
is	NULL
not	NULL
surprising	NULL
considering	NULL
that	NULL
the	NULL
nucleotide	NULL
sequence	NULL
differences	NULL
of	NULL
either	NULL
of	NULL
these	NULL
polymorphic	NULL
sites	NULL
do	NULL
not	NULL
occur	NULL
in	NULL
coding	NULL
regions	NULL
,	NULL
and	NULL
therefore	NULL
do	NULL
not	NULL
alter	NULL
the	NULL
amino	NULL
acid	NULL
sequence	NULL
of	NULL
TCR	NULL
polypeptides	NULL
.	NULL

We	NULL
hypothesize	NULL
that	NULL
these	NULL
RFLPs	NULL
are	NULL
genotypic	NULL
markers	NULL
for	NULL
a	NULL
TCR	NULL
VB	NULL
,	NULL
DS	NULL
,	NULL
or	NULL
J8	NULL
gene	NULL
coding	NULL
for	NULL
the	NULL
variable	NULL
portion	NULL
of	NULL
a	NULL
TCR	NULL
molecule	NULL
that	NULL
recognizes	NULL
the	NULL
Ro	NULL
(	NULL
SSA	NULL
)	NULL
antigen	NULL
in	NULL
patients	NULL
with	NULL
the	NULL
Ro	NULL
(	NULL
SSA	NULL
)	NULL
precipitin	NULL
.	NULL

The	NULL
lack	NULL
of	NULL
a	NULL
complete	NULL
association	NULL
between	NULL
this	NULL
precipitin	NULL
and	NULL
the	NULL
RFLP	NULL
markers	NULL
for	NULL
this	NULL
functional	NULL
gene	NULL
may	NULL
be	NULL
due	NULL
to	NULL
a	NULL
number	NULL
of	NULL
possibilities	NULL
.	NULL

The	NULL
absence	NULL
of	NULL
an	NULL
appropriate	NULL
HLA-encoded	NULL
antigen-presenting	NULL
molecule	NULL
is	NULL
the	NULL
most	NULL
attractive	NULL
hypothesis	NULL
,	NULL
although	NULL
other	NULL
possibilities	NULL
must	NULL
be	NULL
con-sidered	NULL
.	NULL

Recombination	NULL
may	NULL
occur	NULL
between	NULL
these	NULL
markers	NULL
and	NULL
the	NULL
putative	NULL
anti-Ro	NULL
(	NULL
SSA	NULL
)	NULL
TCR	NULL
gene	NULL
,	NULL
or	NULL
a	NULL
second	NULL
TCR	NULL
gene	NULL
may	NULL
be	NULL
involved	NULL
with	NULL
the	NULL
production	NULL
of	NULL
anti-Ro	NULL
(	NULL
SSA	NULL
)	NULL
antibodies	NULL
in	NULL
some	NULL
patients	NULL
.	NULL

Each	NULL
of	NULL
these	NULL
hypotheses	NULL
is	NULL
testable	NULL
once	NULL
such	NULL
a	NULL
functional	NULL
gene	NULL
is	NULL
identified	NULL
.	NULL

We	NULL
may	NULL
also	NULL
have	NULL
failed	NULL
to	NULL
detect	NULL
low	NULL
levels	NULL
of	NULL
anti-Ro	NULL
(	NULL
SSA	NULL
)	NULL
or	NULL
anti-La	NULL
(	NULL
SSB	NULL
)	NULL
antibodies	NULL
in	NULL
some	NULL
of	NULL
the	NULL
patients	NULL
studied	NULL
with	NULL
the	NULL
immunoprecipitation	NULL
methods	NULL
used	NULL
here	NULL
.	NULL

Given	NULL
the	NULL
random	NULL
rearrangement	NULL
of	NULL
VB-D§-J	NULL
$	NULL
8	NULL
exons	NULL
as	NULL
well	NULL
as	NULL
N-region	NULL
diversity	NULL
in	NULL
the	NULL
formation	NULL
of	NULL
a	NULL
functional	NULL
TCR	NULL
variable	NULL
region	NULL
gene	NULL
,	NULL
it	NULL
may	NULL
be	NULL
unusual	NULL
to	NULL
find	NULL
absolute	NULL
associations	NULL
between	NULL
expressed	NULL
TCR	NULL
genes	NULL
and	NULL
human	NULL
diseases	NULL
in	NULL
random	NULL
populations	NULL
.	NULL

Whether	NULL
these	NULL
two	NULL
polymorphic	NULL
sites	NULL
are	NULL
markers	NULL
for	NULL
one	NULL
or	NULL
more	NULL
than	NULL
one	NULL
region	NULL
in	NULL
the	NULL
TCR	NULL
gene	NULL
complex	NULL
can	NULL
not	NULL
be	NULL
determined	NULL
from	NULL
existing	NULL
data	NULL
.	NULL

This	NULL
RFLP	NULL
pair	NULL
may	NULL
be	NULL
a	NULL
marker	NULL
for	NULL
a	NULL
particular	NULL
TCR	NULL
$	NULL
variable	NULL
gene	NULL
component	NULL
.	NULL

The	NULL
close	NULL
proximity	NULL
of	NULL
the	NULL
DB	NULL
and	NULL
J	NULL
8	NULL
genes	NULL
to	NULL
these	NULL
markers	NULL
makes	NULL
them	NULL
more	NULL
likely	NULL
candidates	NULL
than	NULL
V	NULL
$	NULL
genes	NULL
.	NULL

Coding	NULL
sequences	NULL
of	NULL
the	NULL
Df	NULL
and	NULL
JG	NULL
genes	NULL
have	NULL
been	NULL
shown	NULL
to	NULL
be	NULL
of	NULL
critical	NULL
importance	NULL
by	NULL
Rupp	NULL
et	NULL
al	NULL
.	NULL

,	NULL
who	NULL
have	NULL
demonstrated	NULL
that	NULL
differences	NULL
in	NULL
these	NULL
coding	NULL
regions	NULL
confer	NULL
differential	NULL
specificity	NULL
to	NULL
TCR	NULL
molecules	NULL
that	NULL
have	NULL
otherwise	NULL
identical	NULL
VB	NULL
sequences	NULL
(	NULL
50	NULL
)	NULL
.	NULL

While	NULL
recombination	NULL
has	NULL
been	NULL
found	NULL
between	NULL
V/	NULL
and	NULL
C	NULL
#	NULL
genes	NULL
(	NULL
51	NULL
)	NULL
,	NULL
evidence	NULL
for	NULL
linkage	NULL
disequilibrium	NULL
between	NULL
at	NULL
least	NULL
a	NULL
portion	NULL
of	NULL
the	NULL
VB	NULL
genes	NULL
and	NULL
certain	NULL
VB	NULL
and	NULL
C	NULL
#	NULL
genes	NULL
has	NULL
been	NULL
reported	NULL
(	NULL
52	NULL
)	NULL
,	NULL
suggesting	NULL
the	NULL
possibility	NULL
that	NULL
these	NULL
RFLPs	NULL
may	NULL
be	NULL
a	NULL
marker	NULL
for	NULL
a	NULL
TCR	NULL
V	NULL
$	NULL
gene	NULL
.	NULL

However	NULL
,	NULL
the	NULL
weakness	NULL
of	NULL
the	NULL
latter	NULL
association	NULL
may	NULL
imply	NULL
that	NULL
genes	NULL
other	NULL
than	NULL
those	NULL
in	NULL
V	NULL
$	NULL
families	NULL
are	NULL
responsible	NULL
for	NULL
the	NULL
findings	NULL
reported	NULL
here	NULL
.	NULL

Currently	NULL
,	NULL
data	NULL
suggesting	NULL
that	NULL
specific	NULL
sequences	NULL
are	NULL
expressed	NULL
in	NULL
a	NULL
particular	NULL
immune	NULL
response	NULL
remain	NULL
controversial	NULL
.	NULL

On	NULL
the	NULL
one	NULL
hand	NULL
,	NULL
different	NULL
VB	NULL
sequences	NULL
have	NULL
been	NULL
reported	NULL
in	NULL
murine	NULL
MHC-restricted	NULL
T	NULL
cell	NULL
clones	NULL
that	NULL
respond	NULL
to	NULL
defined	NULL
peptide	NULL
determinants	NULL
(	NULL
53	NULL
,	NULL
54	NULL
)	NULL
,	NULL
suggesting	NULL
that	NULL
TCR	NULL
variable	NULL
genes	NULL
alone	NULL
are	NULL
not	NULL
responsible	NULL
for	NULL
specific-ity	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
specific	NULL
VSB	NULL
genes	NULL
seem	NULL
to	NULL
be	NULL
preferentially	NULL
utilized	NULL
in	NULL
murine	NULL
experimental	NULL
allergic	NULL
encephalomyelitis	NULL
and	NULL
collagen-induced	NULL
arthritis	NULL
(	NULL
54-57	NULL
)	NULL
.	NULL

While	NULL
the	NULL
few	NULL
weak	NULL
associations	NULL
of	NULL
VB	NULL
genes	NULL
are	NULL
at	NULL
the	NULL
disease	NULL
rather	NULL
than	NULL
the	NULL
autoantibody	NULL
level	NULL
,	NULL
characterization	NULL
of	NULL
specific	NULL
autoantigens	NULL
and	NULL
the	NULL
T	NULL
cells	NULL
that	NULL
respond	NULL
to	NULL
them	NULL
is	NULL
needed	NULL
to	NULL
determine	NULL
what	NULL
roles	NULL
specific	NULL
TCR	NULL
VB	NULL
genes	NULL
play	NULL
in	NULL
lupus	NULL
and	NULL
other	NULL
human	NULL
autoimmune	NULL
disorders	NULL
characterized	NULL
by	NULL
autoantibodies	NULL
.	NULL

Finally	NULL
,	NULL
one	NULL
of	NULL
these	NULL
RFLPs	NULL
may	NULL
be	NULL
associated	NULL
with	NULL
regulatory	NULL
rather	NULL
than	NULL
coding	NULL
elements	NULL
in	NULL
or	NULL
adjacent	NULL
to	NULL
the	NULL
TCR	NULL
C	NULL
$	NULL
exons	NULL
.	NULL

Recently	NULL
,	NULL
Krimpenfort	NULL
et	NULL
al	NULL
.	NULL

identified	NULL
a	NULL
TCR	NULL
enhancer	NULL
located	NULL
downstream	NULL
of	NULL
the	NULL
C	NULL
#	NULL
2	NULL
gene	NULL
in	NULL
mice	NULL
(	NULL
58	NULL
)	NULL
.	NULL

With	NULL
the	NULL
existing	NULL
data	NULL
we	NULL
can	NULL
not	NULL
eliminate	NULL
more	NULL
complicated	NULL
models	NULL
.	NULL

For	NULL
instance	NULL
,	NULL
one	NULL
of	NULL
the	NULL
RFLPs	NULL
reported	NULL
here	NULL
may	NULL
be	NULL
in	NULL
linkage	NULL
disequilibrium	NULL
with	NULL
a	NULL
variable	NULL
coding	NULL
exon	NULL
and	NULL
the	NULL
other	NULL
with	NULL
a	NULL
polymorphic	NULL
regulatory	NULL
element	NULL
,	NULL
making	NULL
the	NULL
combination	NULL
of	NULL
the	NULL
RFLPs	NULL
a	NULL
marker	NULL
for	NULL
an	NULL
extended	NULL
region	NULL
of	NULL
the	NULL
TCR	NULL
$	NULL
genes	NULL
.	NULL

Our	NULL
observation	NULL
of	NULL
a	NULL
strong	NULL
association	NULL
between	NULL
the	NULL
and	NULL
the	NULL
HLA-DQ	NULL
1	NULL
serotype	NULL
in	NULL
Ro	NULL
(	NULL
SSA	NULL
)	NULL
precipitin-positive	NULL
patients	NULL
is	NULL
particularly	NULL
interesting	NULL
in	NULL
light	NULL
of	NULL
recent	NULL
studies	NULL
of	NULL
HLA-D	NULL
antigens	NULL
and	NULL
the	NULL
presence	NULL
of	NULL
this	NULL
autoantibody	NULL
.	NULL

Hamilton	NULL
et	NULL
al	NULL
.	NULL

(	NULL
15	NULL
)	NULL
found	NULL
a	NULL
significant	NULL
association	NULL
with	NULL
DR2	NULL
(	NULL
and	NULL
DQ1	NULL
with	NULL
which	NULL
it	NULL
is	NULL
in	NULL
linkage	NULL
disequilibrium	NULL
)	NULL
but	NULL
not	NULL
DR3	NULL
(	NULL
or	NULL
DQ2	NULL
)	NULL
in	NULL
SLE	NULL
patients	NULL
with	NULL
the	NULL
Ro	NULL
(	NULL
SSA	NULL
)	NULL
but	NULL
not	NULL
the	NULL
La	NULL
(	NULL
SSB	NULL
)	NULL
antibodies	NULL
,	NULL
again	NULL
suggesting	NULL
that	NULL
it	NULL
is	NULL
this	NULL
group	NULL
of	NULL
patients	NULL
that	NULL
may	NULL
be	NULL
responsible	NULL
for	NULL
these	NULL
findings	NULL
.	NULL

However	NULL
,	NULL
using	NULL
stepwise	NULL
logistic	NULL
regression	NULL
analysis	NULL
in	NULL
this	NULL
and	NULL
other	NULL
reports	NULL
(	NULL
15	NULL
,	NULL
17	NULL
)	NULL
,	NULL
DQ1/DQ2	NULL
heterozygosity	NULL
has	NULL
been	NULL
most	NULL
strongly	NULL
associated	NULL
with	NULL
anti-Ro	NULL
(	NULL
SSA	NULL
)	NULL
antibodies	NULL
.	NULL

Together	NULL
with	NULL
data	NULL
presented	NULL
here	NULL
,	NULL
these	NULL
findings	NULL
allow	NULL
us	NULL
to	NULL
expand	NULL
upon	NULL
a	NULL
previous	NULL
model	NULL
suggesting	NULL
a	NULL
requirement	NULL
for	NULL
gene	NULL
complementation	NULL
between	NULL
HLA-DQ1	NULL
(	NULL
or	NULL
DR2	NULL
)	NULL
and	NULL
HLA-DQ2	NULL
(	NULL
DR3	NULL
)	NULL
associated	NULL
polypeptides	NULL
for	NULL
the	NULL
presentation	NULL
of	NULL
the	NULL
Ro	NULL
(	NULL
SSA	NULL
)	NULL
antigen	NULL
in	NULL
lupus	NULL
and	NULL
Sjogren	NULL
's	NULL
syndrome	NULL
patients	NULL
(	NULL
14	NULL
,	NULL
15	NULL
,	NULL
17	NULL
)	NULL
,	NULL
to	NULL
include	NULL
T	NULL
cells	NULL
whose	NULL
TCR	NULL
polypeptide	NULL
in	NULL
part	NULL
recognizes	NULL
an	NULL
HLA-DQ1-associated	NULL
antigen	NULL
complex	NULL
.	NULL

This	NULL
proposal	NULL
contradicts	NULL
data	NULL
from	NULL
Kotzin	NULL
and	NULL
Palmer	NULL
(	NULL
59	NULL
)	NULL
,	NULL
which	NULL
showed	NULL
that	NULL
mouse	NULL
MHC	NULL
but	NULL
not	NULL
TCR	NULL
genes	NULL
are	NULL
important	NULL
in	NULL
the	NULL
production	NULL
of	NULL
antinuclear	NULL
antibodies	NULL
and	NULL
proteinurea	NULL
in	NULL
the	NULL
(	NULL
NZB	NULL
X	NULL
NZW	NULL
)	NULL
FI1	NULL
model	NULL
of	NULL
lupus	NULL
.	NULL

However	NULL
,	NULL
this	NULL
proposal	NULL
is	NULL
in	NULL
agreement	NULL
with	NULL
three	NULL
other	NULL
reports	NULL
of	NULL
murine	NULL
autoimmune	NULL
disease	NULL
models	NULL
.	NULL

Using	NULL
the	NULL
same	NULL
animal	NULL
model	NULL
as	NULL
Kotzin	NULL
and	NULL
Palmer	NULL
,	NULL
Yanagi	NULL
et	NULL
al	NULL
.	NULL

found	NULL
that	NULL
both	NULL
MHC	NULL
and	NULL
TCRB	NULL
genes	NULL
are	NULL
important	NULL
in	NULL
the	NULL
development	NULL
of	NULL
IgG	NULL
anti-DNA	NULL
antibodies	NULL
and	NULL
circulating	NULL
gp70	NULL
immune	NULL
complexes	NULL
(	NULL
60	NULL
)	NULL
.	NULL

Ghatak	NULL
et	NULL
al	NULL
.	NULL

(	NULL
61	NULL
)	NULL
reported	NULL
that	NULL
both	NULL
MHC	NULL
and	NULL
TCRB	NULL
genes	NULL
are	NULL
associated	NULL
with	NULL
nephritis	NULL
in	NULL
(	NULL
NZB	NULL
X	NULL
SWR	NULL
)	NULL
FI	NULL
mice	NULL
,	NULL
an	NULL
autoimmune	NULL
model	NULL
with	NULL
different	NULL
TCR	NULL
mutations	NULL
than	NULL
that	NULL
mentioned	NULL
above	NULL
(	NULL
62	NULL
)	NULL
,	NULL
Finally	NULL
,	NULL
the	NULL
susceptibility	NULL
to	NULL
collagen-induced	NULL
arthritis	NULL
in	NULL
(	NULL
B10	NULL
X	NULL
SWR	NULL
)	NULL
FL	NULL
hybrid	NULL
mice	NULL
has	NULL
recently	NULL
been	NULL
shown	NULL
to	NULL
be	NULL
associated	NULL
with	NULL
particular	NULL
MHC	NULL
and	NULL
TCRB	NULL
gene	NULL
usage	NULL
by	NULL
Banerjee	NULL
et	NULL
al	NULL
.	NULL

(	NULL
57	NULL
)	NULL
.	NULL

These	NULL
data	NULL
suggest	NULL
that	NULL
restricted	NULL
expression	NULL
of	NULL
TCR	NULL
genes	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
appropriate	NULL
MHC	NULL
gene	NULL
products	NULL
may	NULL
be	NULL
necessary	NULL
for	NULL
the	NULL
development	NULL
of	NULL
particular	NULL
aspects	NULL
of	NULL
autoimmunity	NULL
.	NULL

The	NULL
ability	NULL
to	NULL
appreciate	NULL
the	NULL
genetic	NULL
complexity	NULL
of	NULL
lupus	NULL
may	NULL
lie	NULL
in	NULL
subdividing	NULL
patients	NULL
into	NULL
relatively	NULL
homogeneous	NULL
groups	NULL
for	NULL
study	NULL
.	NULL

The	NULL
use	NULL
of	NULL
specific	NULL
autoantibodies	NULL
in	NULL
this	NULL
report	NULL
is	NULL
a	NULL
classification	NULL
scheme	NULL
that	NULL
appears	NULL
to	NULL
have	NULL
patho-physiologic	NULL
relevance	NULL
.	NULL

Recent	NULL
studies	NULL
have	NULL
demonstrated	NULL
a	NULL
high	NULL
frequency	NULL
of	NULL
anti-Ro	NULL
(	NULL
SSA	NULL
)	NULL
antibodies	NULL
in	NULL
first	NULL
degree	NULL
relatives	NULL
of	NULL
anti-Ro	NULL
(	NULL
SSA	NULL
)	NULL
-positive	NULL
SLE	NULL
patients	NULL
when	NULL
compared	NULL
with	NULL
controls	NULL
(	NULL
63	NULL
)	NULL
.	NULL

Data	NULL
from	NULL
Arnett	NULL
et	NULL
al	NULL
.	NULL

suggest	NULL
that	NULL
both	NULL
MHC	NULL
and	NULL
non-MHC	NULL
genes	NULL
are	NULL
important	NULL
in	NULL
this	NULL
immune	NULL
response	NULL
(	NULL
64	NULL
)	NULL
.	NULL

The	NULL
data	NULL
presented	NULL
here	NULL
provide	NULL
the	NULL
first	NULL
direct	NULL
evidence	NULL
for	NULL
a	NULL
specific	NULL
,	NULL
non-MHC	NULL
gene	NULL
involved	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
anti-Ro	NULL
(	NULL
SSA	NULL
)	NULL
autoantibodies	NULL
.	NULL

These	NULL
data	NULL
are	NULL
the	NULL
first	NULL
to	NULL
show	NULL
an	NULL
association	NULL
between	NULL
a	NULL
TCR	NULL
gene	NULL
and	NULL
a	NULL
known	NULL
human	NULL
autoantigen	NULL
,	NULL
and	NULL
are	NULL
consistent	NULL
with	NULL
a	NULL
model	NULL
proposing	NULL
that	NULL
genes	NULL
at	NULL
multiple	NULL
immune	NULL
response	NULL
loci	NULL
determine	NULL
the	NULL
presence	NULL
of	NULL
particular	NULL
antibodies	NULL
in	NULL
lupus	NULL
patients	NULL
,	NULL
which	NULL
in	NULL
turn	NULL
lead	NULL
to	NULL
the	NULL
differential	NULL
manifestations	NULL
of	NULL
this	NULL
disease	NULL
(	NULL
17	NULL
,	NULL
65	NULL
)	NULL
.	NULL

Acknowledgments	NULL
We	NULL
gratefully	NULL
acknowledge	NULL
Dr.	NULL
J.	NULL
D.	NULL
Capra	NULL
of	NULL
the	NULL
University	NULL
of	NULL
Texas	NULL
Southwestern	NULL
Medical	NULL
Center	NULL
at	NULL
Dallas	NULL
for	NULL
providing	NULL
a	NULL
human	NULL
TCR	NULL
cDNA	NULL
clone	NULL
,	NULL
and	NULL
Laurie	NULL
Soares	NULL
for	NULL
excellent	NULL
technical	NULL
assistance	NULL
in	NULL
isolating	NULL
and	NULL
subcloning	NULL
the	NULL
TCR	NULL
CS	NULL
region	NULL
used	NULL
in	NULL
this	NULL
work	NULL
.	NULL

This	NULL
work	NULL
was	NULL
supported	NULL
by	NULL
grants	NULL
from	NULL
the	NULL
Oklahoma	NULL
Lupus	NULL
Foundation	NULL
,	NULL
the	NULL
Lupus	NULL
Foundation	NULL
of	NULL
America	NULL
,	NULL
Public	NULL
Health	NULL
Service	NULL
grants	NULL
Al-24717	NULL
and	NULL
AR-39577	NULL
,	NULL
the	NULL
March	NULL
of	NULL
Dimes	NULL
Birth	NULL
Defects	NULL
Foundation	NULL
(	NULL
1-1109	NULL
)	NULL
,	NULL
and	NULL
the	NULL
Veteran	NULL
's	NULL
Administration	NULL
.	NULL

Dr.	NULL
Frank	NULL
is	NULL
an	NULL
Alumni	NULL
Research	NULL
Scholar	NULL
of	NULL
the	NULL
University	NULL
of	NULL
Oklahoma	NULL
College	NULL
of	NULL
Medicine	NULL
.	NULL

References	NULL
1	NULL
.	NULL

Leonhardt	NULL
,	NULL
T.	NULL
1964	NULL
.	NULL

Family	NULL
studies	NULL
in	NULL
systemic	NULL
lupus	NULL
erythematosus	NULL
.	NULL

Acta	NULL
Med	NULL
.	NULL

Scand	NULL
.	NULL

176:1-136	NULL
.	NULL

2	NULL
.	NULL

Arnett	NULL
,	NULL
F.	NULL
C.	NULL
,	NULL
and	NULL
L.	NULL
E.	NULL
Shulman	NULL
.	NULL

1976	NULL
.	NULL

Studies	NULL
in	NULL
familial	NULL
systemic	NULL
lupus	NULL
erythematosus	NULL
.	NULL

Medicine	NULL
(	NULL
Baltimore	NULL
)	NULL
.	NULL

55:313-322	NULL
.	NULL

3	NULL
.	NULL

Block	NULL
,	NULL
S.	NULL
R.	NULL
,	NULL
J	NULL
.	NULL

B.	NULL
Winfield	NULL
,	NULL
M.	NULL
D.	NULL
Lockshin	NULL
,	NULL
W.	NULL
A	NULL
.	NULL

D'Angelo	NULL
,	NULL
and	NULL
C.	NULL
L.	NULL
Christian	NULL
.	NULL

1975	NULL
.	NULL

Studies	NULL
of	NULL
twins	NULL
with	NULL
systemic	NULL
lupus	NULL
erythematosus	NULL
:	NULL
a	NULL
review	NULL
of	NULL
the	NULL
literature	NULL
and	NULL
presentation	NULL
of	NULL
12	NULL
additional	NULL
sets	NULL
.	NULL

Am	NULL
.	NULL

J.	NULL
Med	NULL
.	NULL

59:533-552	NULL
.	NULL

4	NULL
.	NULL

Block	NULL
,	NULL
S.	NULL
R.	NULL
,	NULL
M.	NULL
D.	NULL
Lockshin	NULL
,	NULL
J	NULL
.	NULL

B.	NULL
Winfield	NULL
,	NULL
M.	NULL
E.	NULL
Weksler	NULL
,	NULL
I.	NULL
Masakatsu	NULL
,	NULL
R.	NULL
J.	NULL
Winchester	NULL
,	NULL
R.	NULL
C.	NULL
Mellors	NULL
,	NULL
and	NULL
C.	NULL
L.	NULL
Christian	NULL
.	NULL

1976	NULL
.	NULL

Immunologic	NULL
observations	NULL
on	NULL
9	NULL
sets	NULL
of	NULL
twins	NULL
either	NULL
concordant	NULL
or	NULL
discordant	NULL
for	NULL
SLE	NULL
.	NULL

Arthritis	NULL
Rheum	NULL
.	NULL

19:545-554	NULL
.	NULL

T	NULL
Cell	NULL
Receptor	NULL
Genes	NULL
and	NULL
Anti-Ro	NULL
(	NULL
SSA	NULL
)	NULL
Antibodies	NULL
in	NULL
Systemic	NULL
Lupus	NULL
Erythematosus	NULL
__	NULL
37	NULL
5	NULL
.	NULL

Tiwari	NULL
,	NULL
T.	NULL
L.	NULL
,	NULL
and	NULL
P.	NULL
I.	NULL
Terasaki	NULL
.	NULL

1985	NULL
.	NULL

In	NULL
HLA	NULL
and	NULL
Disease	NULL
Associations	NULL
.	NULL

Springer-Verlag	NULL
New	NULL
York	NULL
Inc.	NULL
,	NULL
New	NULL
York	NULL
.	NULL

363-385	NULL
.	NULL

6	NULL
.	NULL

Grumet	NULL
,	NULL
F.	NULL
C.	NULL
,	NULL
A.	NULL
Coukel	NULL
,	NULL
J.	NULL
C.	NULL
Bodmer	NULL
,	NULL
W.	NULL
F.	NULL
Bodmer	NULL
,	NULL
and	NULL
H.	NULL
O.	NULL
McDevitt	NULL
.	NULL

1971	NULL
.	NULL

Histocompatibility	NULL
(	NULL
HL-A	NULL
)	NULL
antigens	NULL
associated	NULL
with	NULL
systemic	NULL
lupus	NULL
erythematosus	NULL
.	NULL

N.	NULL
Engl	NULL
.	NULL

J.	NULL
Med	NULL
.	NULL

285:193-196	NULL
.	NULL

7	NULL
.	NULL

Wilson	NULL
,	NULL
W.	NULL
A.	NULL
,	NULL
E.	NULL
Scopetilis	NULL
,	NULL
and	NULL
J.	NULL
P.	NULL
Michalski	NULL
.	NULL

1984	NULL
.	NULL

Association	NULL
of	NULL
the	NULL
HLA-DR7	NULL
with	NULL
both	NULL
antibody	NULL
to	NULL
SSA	NULL
(	NULL
Ro	NULL
)	NULL
and	NULL
disease	NULL
susceptibility	NULL
in	NULL
blacks	NULL
with	NULL
systemic	NULL
lupus	NULL
erythematosus	NULL
.	NULL

J.	NULL
Rheumatol	NULL
.	NULL

11:653-657	NULL
.	NULL

8	NULL
.	NULL

Howard	NULL
,	NULL
P.	NULL
F.	NULL
,	NULL
M.	NULL
C.	NULL
Hochberg	NULL
,	NULL
W.	NULL
B	NULL
.	NULL

Bias	NULL
,	NULL
F.	NULL
C.	NULL
Arnett	NULL
,	NULL
and	NULL
R.	NULL
H.	NULL
McLean	NULL
.	NULL

1986	NULL
.	NULL

Relationship	NULL
between	NULL
C4	NULL
null	NULL
genes	NULL
,	NULL
HLA-D	NULL
region	NULL
antigens	NULL
,	NULL
and	NULL
antigen	NULL
susceptibility	NULL
to	NULL
systemic	NULL
lupus	NULL
erythematosus	NULL
in	NULL
Caucasian	NULL
and	NULL
Black	NULL
Americans	NULL
.	NULL

Am	NULL
.	NULL

J.	NULL
Med	NULL
.	NULL

81:187-193	NULL
.	NULL

9	NULL
.	NULL

Kemp	NULL
,	NULL
M.	NULL
E.	NULL
,	NULL
J.	NULL
P.	NULL
Atkinson	NULL
,	NULL
V.	NULL
M.	NULL
Skanes	NULL
,	NULL
R.	NULL
P.	NULL
Levine	NULL
,	NULL
and	NULL
D.	NULL
D.	NULL
Chaplin	NULL
.	NULL

1987	NULL
.	NULL

Deletion	NULL
of	NULL
C4A	NULL
genes	NULL
in	NULL
patients	NULL
with	NULL
systemic	NULL
lupus	NULL
erythematosus	NULL
.	NULL

Arthritis	NULL
Rheum	NULL
.	NULL

30:1015-1022	NULL
.	NULL

10	NULL
.	NULL

Goldstein	NULL
,	NULL
R.	NULL
,	NULL
F.	NULL
C.	NULL
Arnett	NULL
,	NULL
R.	NULL
H.	NULL
McLean	NULL
,	NULL
W.	NULL
B	NULL
.	NULL

Bias	NULL
,	NULL
and	NULL
M.	NULL
Duvic	NULL
.	NULL

1988	NULL
.	NULL

Molecular	NULL
heterogeneity	NULL
of	NULL
complement	NULL
component	NULL
C4-null	NULL
and	NULL
21-hydroxylase	NULL
genes	NULL
in	NULL
systemic	NULL
lupus	NULL
erythematosus	NULL
.	NULL

4r-thritis	NULL
Rheum	NULL
.	NULL

31:736-744	NULL
.	NULL

11	NULL
.	NULL

Arnett	NULL
,	NULL
F.	NULL
C.	NULL
,	NULL
R.	NULL
Goldstein	NULL
,	NULL
M.	NULL
Duvic	NULL
,	NULL
and	NULL
J.	NULL
D.	NULL
Reveille	NULL
.	NULL

1988	NULL
.	NULL

Major	NULL
histocompatibility	NULL
complex	NULL
genes	NULL
in	NULL
systemic	NULL
lupus	NULL
erythematosus	NULL
,	NULL
Sjogren	NULL
's	NULL
syndrome	NULL
,	NULL
and	NULL
polymyositis	NULL
.	NULL

Am	NULL
.	NULL

J.	NULL
Med	NULL
.	NULL

85:38-41	NULL
.	NULL

12	NULL
.	NULL

Fielder	NULL
,	NULL
A.	NULL
H.	NULL
L.	NULL
,	NULL
M.	NULL
J.	NULL
Walport	NULL
,	NULL
J.	NULL
R.	NULL
Batchelor	NULL
,	NULL
R.	NULL
I.	NULL
Rynes	NULL
,	NULL
C.	NULL
M.	NULL
Black	NULL
,	NULL
I	NULL
.	NULL

A.	NULL
Dodi	NULL
,	NULL
and	NULL
G.	NULL
R.	NULL
V.	NULL
Hughes	NULL
.	NULL

1983	NULL
.	NULL

Family	NULL
studies	NULL
of	NULL
the	NULL
major	NULL
histocompatibility	NULL
complex	NULL
in	NULL
patients	NULL
with	NULL
systemic	NULL
lupus	NULL
erythematosus	NULL
:	NULL
importance	NULL
of	NULL
null	NULL
alleles	NULL
of	NULL
C4A	NULL
and	NULL
C4B	NULL
in	NULL
determining	NULL
disease	NULL
susceptibility	NULL
.	NULL

Br	NULL
.	NULL

Med	NULL
.	NULL

J	NULL
.	NULL

286:425-428	NULL
.	NULL

13	NULL
.	NULL

Revielle	NULL
,	NULL
J.	NULL
D.	NULL
,	NULL
F.	NULL
C.	NULL
Arnett	NULL
,	NULL
R.	NULL
W.	NULL
Wilson	NULL
,	NULL
W.	NULL
B	NULL
.	NULL

Bias	NULL
,	NULL
and	NULL
R.	NULL
H.	NULL
McLean	NULL
.	NULL

1985	NULL
.	NULL

Null	NULL
alleles	NULL
of	NULL
the	NULL
fourth	NULL
component	NULL
of	NULL
complement	NULL
and	NULL
HLA	NULL
haplotypes	NULL
in	NULL
familial	NULL
systemic	NULL
lupus	NULL
erythematosus	NULL
.	NULL

Immunogenetics	NULL
.	NULL

21:299-311	NULL
.	NULL

14	NULL
.	NULL

Harley	NULL
,	NULL
J	NULL
.	NULL

B.	NULL
,	NULL
M.	NULL
Reichlin	NULL
,	NULL
F.	NULL
C.	NULL
Arnett	NULL
,	NULL
E.	NULL
L.	NULL
Alexander	NULL
,	NULL
W.	NULL
B	NULL
.	NULL

Bias	NULL
,	NULL
and	NULL
T.	NULL
T.	NULL
Provost	NULL
.	NULL

1986	NULL
.	NULL

Gene	NULL
interaction	NULL
at	NULL
HLA-DQ	NULL
enhances	NULL
autoantibody	NULL
production	NULL
in	NULL
primary	NULL
Sjogren	NULL
's	NULL
syndrome	NULL
.	NULL

Science	NULL
(	NULL
Wash.	NULL
DC	NULL
)	NULL
.	NULL

232:1145-1147	NULL
.	NULL

15	NULL
.	NULL

Hamilton	NULL
,	NULL
R.	NULL
G.	NULL
,	NULL
J	NULL
.	NULL

B.	NULL
Harley	NULL
,	NULL
W.	NULL
B	NULL
.	NULL

Bias	NULL
,	NULL
M.	NULL
Roebber	NULL
,	NULL
M.	NULL
Reichlin	NULL
,	NULL
M.	NULL
C.	NULL
Hochberg	NULL
,	NULL
and	NULL
F.	NULL
C.	NULL
Arnett	NULL
.	NULL

1988	NULL
.	NULL

Two	NULL
Ro	NULL
(	NULL
SS-A	NULL
)	NULL
autoantibody	NULL
responses	NULL
in	NULL
systemic	NULL
lupus	NULL
erythematosus	NULL
:	NULL
correlation	NULL
of	NULL
HLA-DR/DQ	NULL
specificities	NULL
with	NULL
quantitative	NULL
expression	NULL
of	NULL
Ro	NULL
(	NULL
SS-A	NULL
)	NULL
autoantibody	NULL
.	NULL

Arthritis	NULL
Rheum	NULL
.	NULL

31:496-505	NULL
.	NULL

16	NULL
.	NULL

Hochberg	NULL
,	NULL
M.	NULL
C.	NULL
,	NULL
R.	NULL
E.	NULL
Boyd	NULL
,	NULL
Jr.	NULL
,	NULL
J.	NULL
M.	NULL
Ahearn	NULL
,	NULL
F.	NULL
C.	NULL
Arnett	NULL
,	NULL
W.	NULL
B	NULL
.	NULL

Bias	NULL
,	NULL
T.	NULL
T.	NULL
Provost	NULL
,	NULL
and	NULL
M.	NULL
B.	NULL
Stevens	NULL
.	NULL

1985	NULL
.	NULL

Systemic	NULL
lupus	NULL
erythematosus	NULL
:	NULL
a	NULL
review	NULL
of	NULL
clinico-laboratory	NULL
features	NULL
and	NULL
immunogenetic	NULL
markers	NULL
in	NULL
150	NULL
patients	NULL
with	NULL
emphasis	NULL
on	NULL
demographic	NULL
subsets	NULL
.	NULL

Medicine	NULL
(	NULL
Baltimore	NULL
)	NULL
.	NULL

64:285-295	NULL
.	NULL

17	NULL
.	NULL

Harley	NULL
,	NULL
J	NULL
.	NULL

B.	NULL
,	NULL
A.	NULL
L.	NULL
Sestak	NULL
,	NULL
L.	NULL
G.	NULL
Willis	NULL
,	NULL
S.	NULL
M.	NULL
Fu	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
Hansen	NULL
,	NULL
and	NULL
M.	NULL
R.	NULL
Reichlin	NULL
.	NULL

1989	NULL
.	NULL

A	NULL
model	NULL
for	NULL
disease	NULL
heterogeneity	NULL
in	NULL
systemic	NULL
lupus	NULL
erythematosus	NULL
:	NULL
relationships	NULL
between	NULL
histocompatibility	NULL
antigens	NULL
,	NULL
autoantibodies	NULL
,	NULL
lymphopenia	NULL
or	NULL
renal	NULL
disease	NULL
.	NULL

Arthritis	NULL
Rheum	NULL
.	NULL

32:826-836	NULL
.	NULL

18	NULL
.	NULL

Bell	NULL
,	NULL
D.	NULL
A.	NULL
,	NULL
and	NULL
P.	NULL
J.	NULL
Maddison	NULL
.	NULL

1980	NULL
.	NULL

Serologic	NULL
subsets	NULL
in	NULL
systemic	NULL
lupus	NULL
erythematosus	NULL
.	NULL

Arthritis	NULL
Rheum	NULL
.	NULL

23:1268-1273	NULL
.	NULL

19	NULL
.	NULL

Clark	NULL
,	NULL
G.	NULL
,	NULL
M.	NULL
Reichlin	NULL
,	NULL
and	NULL
T.	NULL
B.	NULL
Thomas	NULL
,	NULL
Jr.	NULL
1969	NULL
.	NULL

Characterization	NULL
of	NULL
a	NULL
soluble	NULL
cytoplasmic	NULL
antigen	NULL
reactive	NULL
with	NULL
sera	NULL
from	NULL
patients	NULL
with	NULL
systemic	NULL
lupus	NULL
erythematosus	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

102:117-122	NULL
.	NULL

20	NULL
.	NULL

Lerner	NULL
,	NULL
M.	NULL
R.	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
Boyle	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
Hardin	NULL
,	NULL
and	NULL
J	NULL
.	NULL

A.	NULL
Steitz	NULL
.	NULL

1981	NULL
.	NULL

Two	NULL
normal	NULL
classes	NULL
of	NULL
small	NULL
ribonucleoproteins	NULL
detected	NULL
by	NULL
antibodies	NULL
associated	NULL
with	NULL
lupus	NULL
erythematosus	NULL
.	NULL

Science	NULL
(	NULL
Wash.	NULL
DC	NULL
)	NULL
.	NULL

211:400-402	NULL
.	NULL

21	NULL
.	NULL

Reichlin	NULL
,	NULL
M.	NULL
1986	NULL
.	NULL

Significance	NULL
of	NULL
the	NULL
Ro	NULL
antigen	NULL
system	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Immunol	NULL
.	NULL

6:339-348	NULL
.	NULL

22	NULL
.	NULL

Alspaugh	NULL
,	NULL
M.	NULL
A.	NULL
,	NULL
and	NULL
E.	NULL
M.	NULL
Tan	NULL
.	NULL

1975	NULL
.	NULL

Antibodies	NULL
to	NULL
cellular	NULL
antigens	NULL
in	NULL
Sjogren	NULL
's	NULL
syndrome	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

55:1067-1073	NULL
.	NULL

23	NULL
.	NULL

Harley	NULL
,	NULL
J	NULL
.	NULL

B.	NULL
,	NULL
E.	NULL
L.	NULL
Alexander	NULL
,	NULL
W.	NULL
B	NULL
.	NULL

Bias	NULL
,	NULL
O.	NULL
F.	NULL
Fox	NULL
,	NULL
T.	NULL
T.	NULL
Provost	NULL
,	NULL
M.	NULL
Reichlin	NULL
,	NULL
H.	NULL
Yamogata	NULL
,	NULL
and	NULL
F.	NULL
C.	NULL
Arnett	NULL
.	NULL

1986	NULL
.	NULL

Anti-Ro/	NULL
SSA	NULL
and	NULL
anti-La/SSB	NULL
in	NULL
patients	NULL
with	NULL
Sjogren	NULL
's	NULL
syndrome	NULL
.	NULL

Arthritis	NULL
Rheum	NULL
.	NULL

29:196-206	NULL
.	NULL

38	NULL
-	NULL
M.	NULL
B.	NULL
Frank	NULL
,	NULL
R.	NULL
McArthur	NULL
,	NULL
J	NULL
.	NULL

B.	NULL
Harley	NULL
,	NULL
and	NULL
A.	NULL
Fujisaku	NULL
24	NULL
.	NULL

Wasicek	NULL
,	NULL
C.	NULL
A.	NULL
,	NULL
and	NULL
M.	NULL
Reichlin	NULL
.	NULL

1982	NULL
.	NULL

Clinical	NULL
and	NULL
serological	NULL
differences	NULL
between	NULL
systemic	NULL
lupus	NULL
erythematosus	NULL
patients	NULL
with	NULL
antibodies	NULL
to	NULL
Ro	NULL
versus	NULL
patients	NULL
with	NULL
antibodies	NULL
to	NULL
Ro	NULL
and	NULL
La	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

69:835-843	NULL
.	NULL

25	NULL
.	NULL

Mond	NULL
,	NULL
C.	NULL
B.	NULL
,	NULL
M.	NULL
G.	NULL
E.	NULL
Peterson	NULL
,	NULL
and	NULL
N.	NULL
F.	NULL
Rothfield	NULL
.	NULL

1989	NULL
.	NULL

Correlation	NULL
of	NULL
anti-Ro	NULL
antibody	NULL
with	NULL
photosensitivity	NULL
skin	NULL
rash	NULL
in	NULL
systemic	NULL
lupus	NULL
erythematosus	NULL
.	NULL

Arthritis	NULL
Rheum	NULL
.	NULL

32:202-204	NULL
.	NULL

26	NULL
.	NULL

Maddison	NULL
,	NULL
P.	NULL
J.	NULL
,	NULL
H.	NULL
Mogavero	NULL
,	NULL
T.	NULL
T.	NULL
Provost	NULL
,	NULL
and	NULL
M.	NULL
Reichlin	NULL
.	NULL

1979	NULL
.	NULL

The	NULL
clinical	NULL
significance	NULL
of	NULL
antibodies	NULL
to	NULL
a	NULL
soluble	NULL
cytoplasmic	NULL
antigen	NULL
in	NULL
SLE	NULL
and	NULL
other	NULL
connective	NULL
tissue	NULL
diseases	NULL
.	NULL

J.	NULL
Rheumatol	NULL
.	NULL

6:189-195	NULL
.	NULL

27	NULL
.	NULL

Smolen	NULL
,	NULL
J.	NULL
S.	NULL
,	NULL
C.	NULL
Morimoto	NULL
,	NULL
A.	NULL
D.	NULL
Steinberg	NULL
,	NULL
A.	NULL
Wolf	NULL
,	NULL
S.	NULL
F.	NULL
Schlossman	NULL
,	NULL
R.	NULL
T.	NULL
Steinberg	NULL
,	NULL
E.	NULL
Penner	NULL
,	NULL
E.	NULL
Reinherz	NULL
,	NULL
M.	NULL
Reichlin	NULL
,	NULL
and	NULL
T.	NULL
M.	NULL
Chused	NULL
.	NULL

1985	NULL
.	NULL

Systemic	NULL
lupus	NULL
erythematosus	NULL
:	NULL
delineation	NULL
of	NULL
subpopulations	NULL
by	NULL
clinical	NULL
,	NULL
serologic	NULL
and	NULL
T	NULL
cell	NULL
subset	NULL
analysis	NULL
.	NULL

Am	NULL
.	NULL

J.	NULL
Med	NULL
.	NULL

Sci	NULL
.	NULL

289:139-147	NULL
.	NULL

28	NULL
.	NULL

Maddison	NULL
,	NULL
P.	NULL
J.	NULL
,	NULL
and	NULL
M.	NULL
Reichlin	NULL
.	NULL

1979	NULL
.	NULL

Deposition	NULL
of	NULL
antibodies	NULL
to	NULL
a	NULL
soluble	NULL
cytoplasmic	NULL
antigen	NULL
in	NULL
the	NULL
kidneys	NULL
of	NULL
patients	NULL
with	NULL
systemic	NULL
lupus	NULL
erythematosus	NULL
.	NULL

Arthritis	NULL
Rheum	NULL
.	NULL

22:858-863	NULL
.	NULL

29	NULL
.	NULL

Lee	NULL
,	NULL
L.	NULL
A.	NULL
,	NULL
K.	NULL
K.	NULL
Gaither	NULL
,	NULL
S.	NULL
Coulter	NULL
,	NULL
D.	NULL
A.	NULL
Norris	NULL
,	NULL
and	NULL
J	NULL
.	NULL

B.	NULL
Harley	NULL
.	NULL

1989	NULL
.	NULL

The	NULL
pattern	NULL
of	NULL
cutaneous	NULL
IgG	NULL
deposition	NULL
in	NULL
a	NULL
case	NULL
of	NULL
subacute	NULL
cutaneous	NULL
lupus	NULL
erythematosus	NULL
is	NULL
reproduced	NULL
by	NULL
infusing	NULL
purified	NULL
anti-Ro	NULL
(	NULL
SSA	NULL
)	NULL
autoantibodies	NULL
into	NULL
human	NULL
skin-grafted	NULL
mice	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

83:1556-1562	NULL
.	NULL

30	NULL
.	NULL

Scott	NULL
,	NULL
J.	NULL
S.	NULL
,	NULL
P.	NULL
J.	NULL
Maddison	NULL
,	NULL
P.	NULL
V.	NULL
Taylor	NULL
,	NULL
E.	NULL
Esscher	NULL
,	NULL
O.	NULL
Scott	NULL
,	NULL
and	NULL
R.	NULL
P.	NULL
Skinner	NULL
.	NULL

1983	NULL
.	NULL

Connective	NULL
tissue	NULL
disease	NULL
,	NULL
antibodies	NULL
to	NULL
ribonucleoprotein	NULL
and	NULL
congenital	NULL
heart	NULL
block	NULL
.	NULL

N.	NULL
Engl	NULL
.	NULL

J.	NULL
Med	NULL
.	NULL

309:209-212	NULL
.	NULL

31	NULL
.	NULL

Watson	NULL
,	NULL
R.	NULL
M.	NULL
,	NULL
A.	NULL
T.	NULL
Lane	NULL
,	NULL
N.	NULL
K.	NULL
Barnett	NULL
,	NULL
W.	NULL
B	NULL
.	NULL

Bias	NULL
,	NULL
F.	NULL
C.	NULL
Arnett	NULL
,	NULL
and	NULL
T.	NULL
T.	NULL
Provost	NULL
.	NULL

1984	NULL
.	NULL

Neonatal	NULL
lupus	NULL
erythematosus	NULL
:	NULL
a	NULL
clinical	NULL
,	NULL
serological	NULL
and	NULL
immunogenetic	NULL
study	NULL
with	NULL
review	NULL
of	NULL
the	NULL
litera-ture	NULL
.	NULL

Medicine	NULL
(	NULL
Baltimore	NULL
)	NULL
.	NULL

63:362-378	NULL
.	NULL

32	NULL
.	NULL

Taylor	NULL
,	NULL
P.	NULL
V.	NULL
,	NULL
K.	NULL
F.	NULL
Taylor	NULL
,	NULL
A.	NULL
Norman	NULL
,	NULL
S.	NULL
Griffiths	NULL
,	NULL
and	NULL
J.	NULL
S.	NULL
Scott	NULL
.	NULL

1988	NULL
.	NULL

Prevalence	NULL
of	NULL
maternal	NULL
Ro	NULL
(	NULL
SSA	NULL
)	NULL
and	NULL
La	NULL
(	NULL
SSB	NULL
)	NULL
autoantibodies	NULL
in	NULL
relation	NULL
to	NULL
congenital	NULL
heart	NULL
block	NULL
.	NULL

Br	NULL
.	NULL

J.	NULL
Rheumatol	NULL
.	NULL

27:128-132	NULL
.	NULL

33	NULL
.	NULL

Kassan	NULL
,	NULL
S.	NULL
S.	NULL
,	NULL
M.	NULL
Akizuki	NULL
,	NULL
A.	NULL
D.	NULL
Steinberg	NULL
,	NULL
R.	NULL
L.	NULL
Reddick	NULL
,	NULL
and	NULL
T.	NULL
M.	NULL
Chused	NULL
.	NULL

1977	NULL
.	NULL

Antibody	NULL
to	NULL
soluble	NULL
acidic	NULL
nuclear	NULL
antigen	NULL
in	NULL
Sjogren	NULL
's	NULL
syndrome	NULL
.	NULL

Am	NULL
.	NULL

J.	NULL
Med	NULL
.	NULL

63:328-355	NULL
.	NULL

34	NULL
.	NULL

Alspaugh	NULL
,	NULL
M.	NULL
A.	NULL
,	NULL
W.	NULL
W.	NULL
Buchanan	NULL
,	NULL
and	NULL
K.	NULL
Whaley	NULL
.	NULL

1978	NULL
.	NULL

Precipitating	NULL
antibodies	NULL
to	NULL
cellular	NULL
antigens	NULL
in	NULL
Sjogren	NULL
's	NULL
syndrome	NULL
,	NULL
rheumatoid	NULL
arthritis	NULL
,	NULL
and	NULL
other	NULL
organ	NULL
and	NULL
nonorgan-specific	NULL
autoimmune	NULL
disease	NULL
.	NULL

Ann	NULL
.	NULL

Rheum	NULL
.	NULL

Dis	NULL
.	NULL

37:244-247	NULL
.	NULL

35	NULL
.	NULL

Sontheimer	NULL
,	NULL
R.	NULL
D.	NULL
,	NULL
P.	NULL
J.	NULL
Maddison	NULL
,	NULL
M.	NULL
Reichlin	NULL
,	NULL
R.	NULL
E.	NULL
Jordan	NULL
,	NULL
P.	NULL
Stastny	NULL
,	NULL
and	NULL
J.	NULL
N.	NULL
Gilliam	NULL
.	NULL

1982	NULL
.	NULL

Serologic	NULL
and	NULL
HLA	NULL
associations	NULL
in	NULL
subacute	NULL
cutaneous	NULL
lupus	NULL
erythematosus	NULL
,	NULL
a	NULL
clinical	NULL
subset	NULL
of	NULL
lupus	NULL
erythematosus	NULL
.	NULL

Ann	NULL
.	NULL

Intern	NULL
.	NULL

Med	NULL
.	NULL

97:664-671	NULL
.	NULL

36	NULL
.	NULL

Alexander	NULL
,	NULL
E.	NULL
L.	NULL
,	NULL
T.	NULL
J.	NULL
Hirsh	NULL
,	NULL
F.	NULL
C.	NULL
Arnett	NULL
,	NULL
T.	NULL
T.	NULL
Provost	NULL
,	NULL
and	NULL
M.	NULL
B.	NULL
Stevens	NULL
.	NULL

1982	NULL
.	NULL

Ro	NULL
(	NULL
SSA	NULL
)	NULL
and	NULL
La	NULL
(	NULL
SSB	NULL
)	NULL
antibodies	NULL
in	NULL
the	NULL
clinical	NULL
spectrum	NULL
of	NULL
Sjogren	NULL
's	NULL
syndrome	NULL
.	NULL

J.	NULL
Rheumatol	NULL
.	NULL

9:239-246	NULL
.	NULL

37	NULL
.	NULL

Fronek	NULL
,	NULL
Z.	NULL
,	NULL
D.	NULL
Lentz	NULL
,	NULL
N.	NULL
Berliner	NULL
,	NULL
A.	NULL
D.	NULL
Duby	NULL
,	NULL
K.	NULL
A.	NULL
Klein	NULL
,	NULL
J.	NULL
G.	NULL
Seidman	NULL
,	NULL
and	NULL
P.	NULL
H.	NULL
Schur	NULL
.	NULL

1986	NULL
.	NULL

Systemic	NULL
lupus	NULL
erythematosus	NULL
is	NULL
not	NULL
genetically	NULL
linked	NULL
to	NULL
the	NULL
beta	NULL
chain	NULL
of	NULL
the	NULL
T	NULL
cell	NULL
receptor	NULL
.	NULL

Arthritis	NULL
Rheum	NULL
.	NULL

29:1023-1025	NULL
.	NULL

38	NULL
.	NULL

Dunckley	NULL
,	NULL
H.	NULL
,	NULL
P.	NULL
A.	NULL
Gatenby	NULL
,	NULL
and	NULL
S.	NULL
W.	NULL
Serjeantson	NULL
.	NULL

1988	NULL
.	NULL

T-cell	NULL
receptor	NULL
and	NULL
HLA	NULL
class	NULL
II	NULL
RFLPs	NULL
in	NULL
systemic	NULL
lupus	NULL
erythematosus	NULL
.	NULL

Immunogenetics	NULL
.	NULL

27:393-395	NULL
.	NULL

39	NULL
.	NULL

Wong	NULL
,	NULL
D.	NULL
W.	NULL
,	NULL
Z.	NULL
Bentwich	NULL
,	NULL
C.	NULL
Martinez-Tarquino	NULL
,	NULL
J.	NULL
G.	NULL
Seidman	NULL
,	NULL
A.	NULL
D.	NULL
Duby	NULL
,	NULL
T.	NULL
Quertermons	NULL
,	NULL
and	NULL
P.	NULL
H.	NULL
Schur	NULL
.	NULL

1988	NULL
.	NULL

Nonlinkage	NULL
of	NULL
the	NULL
T	NULL
cell	NULL
receptor	NULL
alpha	NULL
,	NULL
beta	NULL
,	NULL
and	NULL
gamma	NULL
genes	NULL
to	NULL
systemic	NULL
lupus	NULL
erythematosus	NULL
in	NULL
multiplex	NULL
families	NULL
.	NULL

Arthritis	NULL
Rheum	NULL
.	NULL

31:1	NULL
371-1376	NULL
.	NULL

40	NULL
.	NULL

Yanagi	NULL
,	NULL
Y.	NULL
,	NULL
Y.	NULL
Yoshikai	NULL
,	NULL
K.	NULL
Legett	NULL
,	NULL
S.	NULL
P.	NULL
Clark	NULL
,	NULL
I.	NULL
Aleksander	NULL
,	NULL
and	NULL
T.	NULL
Mak	NULL
.	NULL

1984	NULL
.	NULL

A	NULL
human	NULL
T-cell	NULL
specific	NULL
cDNA	NULL
clone	NULL
encodes	NULL
a	NULL
protein	NULL
having	NULL
extensive	NULL
homology	NULL
to	NULL
immunoglobulin	NULL
chains	NULL
.	NULL

Nature	NULL
(	NULL
Lond	NULL
.	NULL
)	NULL

.	NULL

45-149	NULL
.	NULL

41	NULL
.	NULL

Cohen	NULL
,	NULL
S.	NULL
N.	NULL
,	NULL
A.	NULL
C.	NULL
Y.	NULL
Chang	NULL
,	NULL
and	NULL
L.	NULL
Hsu	NULL
.	NULL

1969	NULL
.	NULL

Nonchromo-somal	NULL
antibiotic	NULL
resistance	NULL
in	NULL
bacteria	NULL
:	NULL
genetic	NULL
transformation	NULL
of	NULL
Escherichia	NULL
coli	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
.	NULL

69:2110-2114	NULL
.	NULL

42	NULL
.	NULL

Tan	NULL
,	NULL
E.	NULL
M.	NULL
,	NULL
A.	NULL
S.	NULL
Cohen	NULL
,	NULL
J.	NULL
F.	NULL
Fries	NULL
,	NULL
A.	NULL
T.	NULL
Masi	NULL
,	NULL
D.	NULL
J.	NULL
McShane	NULL
,	NULL
N.	NULL
F.	NULL
Rothfield	NULL
,	NULL
J.	NULL
G.	NULL
Schaller	NULL
,	NULL
N.	NULL
Talal	NULL
,	NULL
and	NULL
R.	NULL
J.	NULL
Winchester	NULL
.	NULL

1982	NULL
.	NULL

The	NULL
1982	NULL
revised	NULL
criteria	NULL
for	NULL
the	NULL
classification	NULL
of	NULL
systemic	NULL
lupus	NULL
erythematosus	NULL
.	NULL

Arthritis	NULL
Rheum	NULL
.	NULL

25:1271-1277	NULL
.	NULL

43	NULL
.	NULL

Southern	NULL
,	NULL
E.	NULL
M.	NULL
1978	NULL
.	NULL

Detection	NULL
of	NULL
specific	NULL
sequences	NULL
among	NULL
DNA	NULL
fragments	NULL
separated	NULL
by	NULL
gel	NULL
electrophoresis	NULL
.	NULL

J.	NULL
Mol	NULL
.	NULL

Biol	NULL
.	NULL

98:503-517	NULL
.	NULL

44	NULL
.	NULL

Feinberg	NULL
,	NULL
A.	NULL
P.	NULL
,	NULL
and	NULL
B.	NULL
Vogelstein	NULL
.	NULL

1983	NULL
.	NULL

A	NULL
technique	NULL
for	NULL
radiolabeling	NULL
DNA	NULL
restriction	NULL
endonuclease	NULL
fragments	NULL
to	NULL
high	NULL
specific	NULL
activity	NULL
.	NULL

Anal	NULL
.	NULL

Biochem	NULL
.	NULL

132:6-13	NULL
.	NULL

45	NULL
.	NULL

Feinberg	NULL
,	NULL
A.	NULL
P.	NULL
,	NULL
and	NULL
B.	NULL
Vogelstein	NULL
.	NULL

1984	NULL
.	NULL

Addendum	NULL
:	NULL
a	NULL
technique	NULL
for	NULL
radiolabeling	NULL
DNA	NULL
restriction	NULL
endonuclease	NULL
fragments	NULL
to	NULL
high	NULL
specific	NULL
activity	NULL
.	NULL

Anal	NULL
.	NULL

Biochem	NULL
.	NULL

137:266-267	NULL
.	NULL

46	NULL
.	NULL

Robinson	NULL
,	NULL
M.	NULL
A.	NULL
,	NULL
and	NULL
T.	NULL
J.	NULL
Kindt	NULL
.	NULL

1985	NULL
.	NULL

Segregation	NULL
of	NULL
polymorphic	NULL
T-cell	NULL
receptor	NULL
genes	NULL
in	NULL
human	NULL
families	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
.	NULL

82:3804-3808	NULL
.	NULL

47	NULL
.	NULL

Oksenberg	NULL
,	NULL
J.	NULL
R.	NULL
,	NULL
C.	NULL
N.	NULL
Gaiser	NULL
,	NULL
L.	NULL
L.	NULL
Cavalli-Sforza	NULL
,	NULL
and	NULL
L.	NULL
Steinman	NULL
.	NULL

1988	NULL
.	NULL

Polymorphic	NULL
markers	NULL
of	NULL
human	NULL
T-cell	NULL
receptor	NULL
alpha	NULL
and	NULL
beta	NULL
genes	NULL
:	NULL
family	NULL
studies	NULL
and	NULL
comparison	NULL
of	NULL
frequencies	NULL
in	NULL
healthy	NULL
individuals	NULL
and	NULL
patients	NULL
with	NULL
multiple	NULL
sclerosis	NULL
and	NULL
myasthe-nia	NULL
gravis	NULL
California	NULL
94305	NULL
.	NULL

Hum	NULL
.	NULL

Immunol	NULL
.	NULL

22	NULL
:	NULL
111-121	NULL
.	NULL

48	NULL
.	NULL

Berliner	NULL
,	NULL
N.	NULL
,	NULL
A.	NULL
D.	NULL
Duby	NULL
,	NULL
C.	NULL
C.	NULL
Morton	NULL
,	NULL
P.	NULL
Leder	NULL
,	NULL
and	NULL
J.	NULL
G.	NULL
Seidman	NULL
.	NULL

1985	NULL
.	NULL

Detection	NULL
of	NULL
a	NULL
frequent	NULL
restriction	NULL
fragment	NULL
length	NULL
polymorphism	NULL
in	NULL
the	NULL
human	NULL
T	NULL
cell	NULL
antigen	NULL
receptor	NULL
beta	NULL
chain	NULL
locus	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

76:1283-1285	NULL
.	NULL

49	NULL
.	NULL

Toyonaga	NULL
,	NULL
B.	NULL
,	NULL
Y.	NULL
Yoshikai	NULL
,	NULL
V.	NULL
Vadasz	NULL
,	NULL
B.	NULL
Chin	NULL
,	NULL
and	NULL
T.	NULL
Mak	NULL
.	NULL

1985	NULL
.	NULL

Organization	NULL
and	NULL
sequences	NULL
of	NULL
the	NULL
diversity	NULL
,	NULL
joining	NULL
,	NULL
and	NULL
constant	NULL
region	NULL
genes	NULL
of	NULL
the	NULL
human	NULL
T-cell	NULL
receptor	NULL
beta	NULL
chain	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
.	NULL

$	NULL
2:8624-8628	NULL
.	NULL

50	NULL
.	NULL

Rupp	NULL
,	NULL
F.	NULL
,	NULL
J.	NULL
Brecher	NULL
,	NULL
M.	NULL
A.	NULL
Giedlin	NULL
,	NULL
T.	NULL
Mosmann	NULL
,	NULL
R.	NULL
M.	NULL
Zinkernagel	NULL
,	NULL
H.	NULL
Hengartner	NULL
,	NULL
and	NULL
R.	NULL
H.	NULL
Joho	NULL
.	NULL

1987	NULL
.	NULL

T-cell	NULL
antigen	NULL
receptors	NULL
with	NULL
identical	NULL
variable	NULL
regions	NULL
but	NULL
different	NULL
diversity	NULL
and	NULL
joining	NULL
region	NULL
gene	NULL
segments	NULL
have	NULL
distinct	NULL
specificities	NULL
but	NULL
cross-reac-tive	NULL
idiotypes	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
.	NULL

84:219-222	NULL
.	NULL

51	NULL
.	NULL

Robinson	NULL
,	NULL
M.	NULL
A.	NULL
,	NULL
and	NULL
T.	NULL
J.	NULL
Kindt	NULL
.	NULL

1986	NULL
.	NULL

Molecular	NULL
genotyping	NULL
of	NULL
human	NULL
T-cell	NULL
antigen	NULL
receptor	NULL
variable	NULL
gene	NULL
segments	NULL
.	NULL

Immunogenetics	NULL
.	NULL

24:259-266	NULL
.	NULL

52	NULL
.	NULL

Concannon	NULL
,	NULL
P.	NULL
,	NULL
R.	NULL
A.	NULL
Gatti	NULL
,	NULL
and	NULL
L.	NULL
E.	NULL
Hood	NULL
.	NULL

1987	NULL
.	NULL

Human	NULL
T	NULL
cell	NULL
receptor	NULL
V	NULL
beta	NULL
gene	NULL
polymorphism	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

165:1	NULL
130-1140	NULL
.	NULL

53	NULL
.	NULL

Kronenberg	NULL
,	NULL
M.	NULL
,	NULL
G.	NULL
Siu	NULL
,	NULL
L.	NULL
E.	NULL
Hood	NULL
,	NULL
and	NULL
N.	NULL
Shastri	NULL
.	NULL

1986	NULL
.	NULL

The	NULL
molecular	NULL
genetics	NULL
of	NULL
the	NULL
T-cell	NULL
antigen	NULL
receptor	NULL
and	NULL
T-cell	NULL
antigen	NULL
recognition	NULL
.	NULL

Annu	NULL
.	NULL

Rev	NULL
.	NULL

Immunol	NULL
.	NULL

4:529-591	NULL
.	NULL

54	NULL
.	NULL

Acha-Orbea	NULL
,	NULL
H.	NULL
,	NULL
L.	NULL
Steinman	NULL
,	NULL
and	NULL
H.	NULL
O.	NULL
McDevitt	NULL
.	NULL

1989	NULL
.	NULL

T	NULL
cell	NULL
receptors	NULL
in	NULL
murine	NULL
autoimmune	NULL
diseases	NULL
.	NULL

Annu	NULL
.	NULL

Rev	NULL
.	NULL

Immunol	NULL
.	NULL

7:371-405	NULL
.	NULL

55	NULL
.	NULL

Urban	NULL
,	NULL
J.	NULL
L.	NULL
,	NULL
V.	NULL
Kumar	NULL
,	NULL
D.	NULL
H.	NULL
Kono	NULL
,	NULL
C.	NULL
Gomez	NULL
,	NULL
S.	NULL
J.	NULL
Horvath	NULL
,	NULL
J.	NULL
Clayton	NULL
,	NULL
D.	NULL
G.	NULL
Ando	NULL
,	NULL
E.	NULL
E.	NULL
Sercarz	NULL
,	NULL
and	NULL
L.	NULL
Hood	NULL
.	NULL

1988	NULL
.	NULL

Restricted	NULL
use	NULL
of	NULL
T	NULL
cell	NULL
receptor	NULL
V	NULL
genes	NULL
in	NULL
murine	NULL
autoimmune	NULL
encephalomyelitis	NULL
raises	NULL
possibilities	NULL
for	NULL
antibody	NULL
therapy	NULL
.	NULL

Cell	NULL
.	NULL

54:577-592	NULL
.	NULL

56	NULL
.	NULL

Acha-Orbea	NULL
,	NULL
H.	NULL
,	NULL
D.	NULL
J.	NULL
Mitchell	NULL
,	NULL
L.	NULL
Timmermann	NULL
,	NULL
D.	NULL
C.	NULL
Wraith	NULL
,	NULL
G.	NULL
S.	NULL
Tausch	NULL
,	NULL
M.	NULL
K.	NULL
Waldor	NULL
,	NULL
S.	NULL
S.	NULL
Zamvil	NULL
,	NULL
H.	NULL
O.	NULL
McDevitt	NULL
,	NULL
and	NULL
L.	NULL
Steinman	NULL
.	NULL

1988	NULL
.	NULL

Limited	NULL
heterogeneity	NULL
of	NULL
T	NULL
cell	NULL
receptors	NULL
from	NULL
lymphocytes	NULL
mediating	NULL
autoimmune	NULL
encephalomyelitis	NULL
allows	NULL
specific	NULL
immune	NULL
intervention	NULL
.	NULL

Cell	NULL
.	NULL

54:263-273	NULL
.	NULL

57	NULL
.	NULL

Banerjee	NULL
,	NULL
S.	NULL
,	NULL
T.	NULL
M.	NULL
Hagi	NULL
,	NULL
H.	NULL
S.	NULL
Luthra	NULL
,	NULL
J.	NULL
M.	NULL
Stuart	NULL
,	NULL
and	NULL
C.	NULL
S.	NULL
David	NULL
.	NULL

1988	NULL
.	NULL

Possible	NULL
role	NULL
of	NULL
V	NULL
beta	NULL
T	NULL
cell	NULL
receptor	NULL
genes	NULL
in	NULL
susceptibility	NULL
to	NULL
collagen-induced	NULL
arthritis	NULL
in	NULL
mice	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

167:832-839	NULL
.	NULL

58	NULL
.	NULL

Krimpenfort	NULL
,	NULL
P.	NULL
,	NULL
R.	NULL
de	NULL
Jong	NULL
,	NULL
Y.	NULL
Uematsu	NULL
,	NULL
Z.	NULL
Dembic	NULL
,	NULL
S.	NULL
Ryser	NULL
,	NULL
H.	NULL
von	NULL
Boehmer	NULL
,	NULL
M.	NULL
Steinmetz	NULL
,	NULL
and	NULL
A.	NULL
Berns	NULL
.	NULL

1988	NULL
.	NULL

Transcription	NULL
of	NULL
T	NULL
cell	NULL
receptor	NULL
beta-chain	NULL
genes	NULL
is	NULL
controlled	NULL
by	NULL
a	NULL
downstream	NULL
regulatory	NULL
element	NULL
.	NULL

EMBO	NULL
(	NULL
Eur	NULL
.	NULL

Mol	NULL
.	NULL

Biol	NULL
.	NULL

Organ	NULL
.	NULL
)	NULL

J	NULL
.	NULL

7:745-750	NULL
.	NULL

59	NULL
.	NULL

Kotzin	NULL
,	NULL
B.	NULL
L.	NULL
,	NULL
and	NULL
E.	NULL
Palmer	NULL
.	NULL

1987	NULL
.	NULL

The	NULL
contribution	NULL
of	NULL
NZW	NULL
genes	NULL
to	NULL
lupus-like	NULL
disease	NULL
in	NULL
(	NULL
NZB	NULL
X	NULL
NZW	NULL
)	NULL
FI	NULL
mice	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

165:1237-1251	NULL
.	NULL

60	NULL
.	NULL

Yanagi	NULL
,	NULL
Y.	NULL
,	NULL
S.	NULL
Hirose	NULL
,	NULL
R.	NULL
Nagasawa	NULL
,	NULL
T.	NULL
Shirai	NULL
,	NULL
T.	NULL
W.	NULL
Mak	NULL
,	NULL
and	NULL
T.	NULL
Tada	NULL
.	NULL

1986	NULL
.	NULL

Does	NULL
the	NULL
deletion	NULL
within	NULL
T	NULL
cell	NULL
receptor	NULL
beta-chain	NULL
gene	NULL
of	NULL
NZW	NULL
mice	NULL
contribute	NULL
to	NULL
autoimmunity	NULL
in	NULL
(	NULL
NZB	NULL
X	NULL
NZW	NULL
)	NULL
FI	NULL
mice	NULL
?	NULL

Eur	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

16:1179-1182	NULL
.	NULL

61	NULL
.	NULL

Ghatak	NULL
,	NULL
S.	NULL
,	NULL
K.	NULL
Sainis	NULL
,	NULL
F.	NULL
L.	NULL
Owen	NULL
,	NULL
and	NULL
S.	NULL
K.	NULL
Datta	NULL
.	NULL

1987	NULL
.	NULL

T-cell-receptor	NULL
beta-	NULL
and	NULL
I-A	NULL
beta-chain	NULL
genes	NULL
of	NULL
normal	NULL
SWR	NULL
mice	NULL
are	NULL
linked	NULL
with	NULL
the	NULL
development	NULL
of	NULL
lupus	NULL
nephritis	NULL
in	NULL
NZB	NULL
X	NULL
SWR	NULL
crosses	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
.	NULL

84:6850-6853	NULL
.	NULL

62	NULL
.	NULL

Kotzin	NULL
,	NULL
B.	NULL
L.	NULL
,	NULL
V.	NULL
L.	NULL
Barr	NULL
,	NULL
and	NULL
E.	NULL
Palmer	NULL
.	NULL

1985	NULL
.	NULL

A	NULL
large	NULL
deletion	NULL
within	NULL
the	NULL
T-cell	NULL
receptor	NULL
beta-chain	NULL
gene	NULL
complex	NULL
in	NULL
New	NULL
Zealand	NULL
white	NULL
mice	NULL
.	NULL

Science	NULL
(	NULL
Wash.	NULL
DC	NULL
)	NULL
.	NULL

229:167-171	NULL
.	NULL

63	NULL
.	NULL

Lehman	NULL
,	NULL
T.	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
V.	NULL
Hanson	NULL
,	NULL
N.	NULL
Zvaifler	NULL
,	NULL
G.	NULL
Sharp	NULL
,	NULL
and	NULL
M.	NULL
Alspaugh	NULL
.	NULL

1984	NULL
.	NULL

Antibodies	NULL
to	NULL
nonhistone	NULL
nuclear	NULL
antigen	NULL
and	NULL
anti-lymphocyte	NULL
antibodies	NULL
among	NULL
children	NULL
and	NULL
adults	NULL
with	NULL
systemic	NULL
lupus	NULL
erythematosus	NULL
.	NULL

J.	NULL
Rheumatol	NULL
.	NULL

11:644-647	NULL
.	NULL

64	NULL
.	NULL

Arnett	NULL
,	NULL
F.	NULL
C.	NULL
,	NULL
R.	NULL
G.	NULL
Hamilton	NULL
,	NULL
W.	NULL
B	NULL
.	NULL

Bias	NULL
,	NULL
J.	NULL
D.	NULL
Reveille	NULL
,	NULL
J	NULL
.	NULL

B.	NULL
Harley	NULL
,	NULL
and	NULL
M.	NULL
Reichlin	NULL
.	NULL

1989	NULL
.	NULL

Genetic	NULL
studies	NULL
of	NULL
Ro	NULL
(	NULL
SS-A	NULL
)	NULL
and	NULL
La	NULL
(	NULL
SS-B	NULL
)	NULL
autoantibodies	NULL
detected	NULL
by	NULL
ELISA	NULL
in	NULL
families	NULL
with	NULL
systemic	NULL
lupus	NULL
erythematosus	NULL
and	NULL
primary	NULL
Sjogren	NULL
's	NULL
syndrome	NULL
.	NULL

Arthritis	NULL
Rheum	NULL
.	NULL

32:413-419	NULL
.	NULL

65	NULL
.	NULL

Harley	NULL
,	NULL
J	NULL
.	NULL

B.	NULL
,	NULL
and	NULL
K.	NULL
K.	NULL
Gaither	NULL
.	NULL

1988	NULL
.	NULL

Autoantibodies	NULL
.	NULL

Rheum	NULL
.	NULL

Dis	NULL
.	NULL

Clin	NULL
.	NULL

North	NULL
Am	NULL
.	NULL

14:43-56	NULL
.	NULL

T	NULL
Cell	NULL
Receptor	NULL
Genes	NULL
and	NULL
Anti-Ro	NULL
(	NULL
SSA	NULL
)	NULL
Antibodies	NULL
in	NULL
Systemic	NULL
Lupus	NULL
Erythematosus	NULL
__	NULL
39	NULL

